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ABSTRACT  
   
Chromatin is the dynamic structure of proteins and nucleic acids into which 
eukaryotic genomes are organized. For those looking to engineer mammalian 
genomes, chromatin is both an opportunity and an obstacle. While chromatin 
provides another tool with which to control gene expression, regional density can 
lead to variability in genome editing efficiency by CRISPR/Cas9 systems. Many 
groups have attempted to de-silence chromatin to regulate genes and enhance 
DNA's accessibility to nucleases, but inconsistent results leave outstanding questions. 
Here, I test different types of activators, to analyze changes in chromatin features 
that result for chromatin opening, and to identify the critical biochemical features 
that support artificially generated open, transcriptionally active chromatin. 
I designed, built, and tested a panel of synthetic pioneer factors (SPiFs) to 
open condensed, repressive chromatin with the aims of 1) activating repressed 
transgenes in mammalian cells and 2) reversing the inhibitory effects of closed 
chromatin on Cas9-endonuclease activity. Pioneer factors are unique in their ability 
to bind DNA in closed chromatin. In order to repurpose this natural function, I 
designed SPiFs from a Gal4 DNA binding domain, which has inherent pioneer 
functionality, fused with chromatin-modifying peptides with distinct functions.  
SPiFs with transcriptional activation as their primary mechanism were able to 
reverse this repression and induced a stably active state. My work also revealed the 
active site from proto-oncogene MYB as a novel transgene activator. To determine if 
MYB could be used generally to restore transgene expression, I fused it to a 
deactivated Cas9 and targeted a silenced transgene in native heterochromatin. The 
resulting activator was able to reverse silencing and can be chemically controlled 
with a small molecule drug.  
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Other SPiFs in my panel did not increase gene expression. However, 
pretreatment with several of these expression-neutral SPiFs increased Cas9-
mediated editing in closed chromatin, suggesting a crucial difference between 
chromatin that is accessible and that which contains genes being actively 
transcribed. Understanding this distinction will be vital to the engineering of stable 
transgenic cell lines for product production and disease modeling, as well as 
therapeutic applications such as restoring epigenetic order to misregulated disease 
cells.
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CHAPTER 1 
 
INTRODUCTION☨ 
 
 
 
1.1 Unlocking Access to DNA in Chromatin 
 
The genomes of eukaryotic cells are condensed into a complex, organized 
nucleo-protein structure known as chromatin. Chromatin dynamically regulates gene 
expression by locally altering the density of DNA packaging and associations with 
chromatin remodeling factors (Bintu et al.; Libbrecht et al.; Bowman and McKnight). 
Tightly compacted areas of chromatin, known as heterochromatin, directly inhibit 
associations between DNA and transcriptional machinery by preventing the 
recognition of DNA binding sites (Johnson et al.; Janssen et al.). This closed state is 
characterized by silencing marks, repressive protein collocation, and a density of 
linker histones that together form condensed structures that are difficult to disrupt 
(Figure 1.1) (Arrighi and Hsu; Peng; Erdel and Rippe). The DNA within is generally 
inaccessible to DNA binding proteins, thus prohibiting active gene expression. Open 
chromatin, or euchromatin, is characterized by an accessible, loose structure, and 
activation-associated chemical modifications (Figure 1.1) (Wolffe and Urnov). This 
non-compacted structure allows access for transcriptional machinery and is thus 
associated with active transcription.  
____________________________________ 
☨Sections of this chapter are based on an article previously published in Chemical Engineering Progress 
(CEP). The original citation is Barrett, C. M., et al. (2018). Unlocking Access to DNA in Chromatin. CEP 
Magazine, SBE Special Selection: Epigenetics. Any text and figures reproduced here are done so with 
explicit permission from AIChE Publishing. See Appendix D for permissions and authorships. 
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As synthetic biology advances, its practitioners are constantly seeking out 
new chassis in which to execute increasingly intricate designs and with which to 
manufacture more complex products, such as therapeutic antibodies. This has 
naturally led to the engineering of mammalian cell lines, including human lines to 
construct disease models and therapeutic molecular machines. While the complexity 
of this chassis may be desirable in that it provides more opportunities for 
engineering, increased system complexity also increases variability in engineering 
outcomes. This is evidenced by the impacts of chromatin on engineered mammalian 
cell lines. While site-specific chromatin manipulation provides an additional layer of 
gene expression control, native chromatin can interfere with transgenic systems. 
Gaining reliable, controlled access to the (epi)genome is an important step toward 
realizing the full potential of synthetic biology in mammalian chassis.  
A perennial source of variability that thwarts this reliable access, is the 
natural condensation of chromatin around inserted transgenes (Meyer). Native 
defense mechanisms often epigenetically silence inserted genetic material, posing a 
challenge to the construction of stable mammalian cell line (Leung and Lorincz; Ross 
et al.; Ellis; Ngai). Part of the key to unlocking chromatin will be to develop a suite of 
tools that can reliably reverse transgene silencing. We must also understand the 
impact that chromatin has on editing tools such as small-RNA-guided nucleases 
(CRISPR/Cas9), as well as protein-DNA binding nucleases such as transcription 
activator-like effector nucleases (TALENs) and zinc finger nucleases (ZF) that all rely 
directly on DNA binding interactions to achieve editing.  
To unlock access to the genome, we need to understand the answers to a few 
vital questions: 1) What specific features of chromatin impact DNA accessibility to 
endogenous and exogenous effectors? 2) How do these features perturb stable 
engagement of gene-editing enzymes with their targets? And, 3) how can we 
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manipulate chromatin to overcome transgene silencing and inhibition of gene-editing 
activity?  
Much work has already been done to understand the first two of these 
questions. This chapter will review that work by addressing 1) what is known about 
how the structural elements of chromatin affect accessibility and 2) how chromatin 
impacts transgene expression and CRISPR/Cas9 function as well as the few studies 
that have attempted to improve CRISPR/Cas9-mediated editing in heterochromatin. I 
will then review a series of major methods employed by the cell to open chromatin 
that may be harnessed by engineers to do the same in order to regulate gene 
expression and chromatin state. I review the mechanism behind each method, its 
potential to be engineered, and previous attempts to do so. Finally, I propose 
remaining challenges to the opening of chromatin as well as important design 
parameters that warrant further investigation. Several of these native chromatin-
opening mechanisms are underexplored or have never been the subject of any 
molecular engineering. Testing and comparing these chromatin-opening approaches, 
as well as addressing nuanced design parameters outlined at the end of this chapter, 
set up the motivation for the remained of this work.  
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Figure 1.1: Chromatin architecture impacts accessibility. The core structure of 
chromatin is the nucleosome, an octamer of distinct histone proteins, around which 
DNA is wound. Highly compacted areas of chromatin are characterized by the 
localization of repressor complexes, repressive histone tail modifications, and linker 
histones that bring adjacent nucleosomes into close contact. This dense structure 
creates a liquid-like compartment through phase separation that precludes the 
interaction of DNA binding proteins such as editing endonucleases with DNA. Loosely 
packaged chromatin or euchromatin allows for active transcription of DNA and 
interaction with binding factors. Histone tail acetylation in euchromatin recruits these 
associated factors. (Reprinted with permission from Chemical Engineering Progress 
(CEP). Copyright © 2018 American Institute of Chemical Engineers (AIChE)) 
 
 
1.1.1    Core Structural Elements of Chromatin Impact Accessibility 
 
The primary structural unit of chromatin is the nucleosome. Nucleosomes are 
comprised of a 147 base pair length of DNA wound around an octamer of four core 
histone proteins (Figure 1.1). Protruding from the histone H32H42  tetramer are 
unstructured amino acid tails that can be chemically modified with either activating 
or silencing marks (Figure 1.1). Arrays of nucleosomes can be assembled into higher 
order structures through small-scale interactions such as the binding of linker 
histones near the nucleosome dyad axis (Zhou et al.) or co-localization of repressor 
  5 
complexes (Fan et al.). These structures may be further organized and compacted 
through interactions with distant genomic domains through phase separation and the 
weaving of chromosomal structures through interactions of chromatin with the 
nuclear envelope (Figure 1.1) (Erdel and Rippe). DNA at the histone-octamer 
interface is shielded from the nuclear environment. Furthermore, bending of the DNA 
around the histone complex distorts the width of the major groove in the double 
helix, resulting in a suboptimal fit for ZF proteins that interact with B-form DNA 
(Figure 1.1) (Luger et al.). Through this mechanisms nucleosome positioning 
dynamically regulates the genome (Bai and Morozov) as dense local nucleosome 
occupancy on the chromatin fiber precludes DNA accessibility to transcription factors 
(TFs) and other DNA binding proteins involved in transcription, replication and repair.  
Nucleosome positioning dynamically regulates the genome. Dense local 
nucleosome occupancy on the chromatin fiber precludes transcription factors (TFs) 
and other DNA binding proteins involved in transcription, replication, and repair from 
accessing DNA. In assays where nucleases are used to cut DNA within whole 
nucleosomes, high levels of cleavage reproducibly distinguish open chromatin 
regions, whereas closed chromatin regions show low levels of cleavage (Tsompana 
and Buck). Physical interactions between endogenous nuclear proteins and DNA 
block the nucleases from accessing the DNA, further supporting the concept that 
access to DNA is influenced by chromatin structure.  
 How then, within this dense throng, do TFs and other DNA binding proteins 
still ultimately find their binding domains? The congregated and compacted nature of 
the eukaryotic genome is a dynamic physical barrier to any process that requires 
accessible DNA. Nucleosome positioning is regulated by several factors that 
determine local accessibility. Some DNA sequences directly inhibit or, conversely, 
favor nucleosome occupancy (Struhl and Segal). Additionally, nucleosomes bound to 
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DNA can be displaced by ATP-dependent chromatin remodelers or certain classes of 
pioneer transcription factors (PFs) that can regulate nucleosome position (Struhl and 
Segal). This displacement of nucleosomes directly increases accessibility to DNA 
binding factors. For example, high nucleosome density at promoter regions directly 
blocks the initiation of transcription (Lorch et al.) while depletion of nucleosomes at 
promoters facilitates RNA polymerase II binding and thus the initiation of 
transcription (Ichikawa et al.). While dynamic regulation of nucleosome occupancy 
allows the cell to regulate transcription, it more generally increases DNA accessibility 
for any binding protein, making nucleosome depletion an attractive option for 
opening chromatin. 
 
1.1.2    Opening Chromatin to Activate Gene Expression 
 
The site-specific opening of chromatin to activate gene expression is an 
invaluable tool for mammalian synthetic biologists. Orchestrating the activation of 
specific genes within the cell allows us to alter cell type (Black et al.), replicate gene 
expression profiles to create disease models (Hurtado Del Pozo et al.), and shift 
metabolic loads to increase product yields. Epigenetic activators can themselves be 
used as components of constructs for biosensing, computing, or other applications 
such as toggle switches or represilators (Kramer et al.; Perez-Carrasco et al.; Lei). 
Furthermore, these activators can be used to return gene expression to a desired 
state, either by reversing abnormal silencing in diseased cells (such as cancer) or 
reversing the undesired silencing of transgenes.  
Targeted opening of chromatin in order to control gene expression state has 
been successfully achieved with two mechanisms: the deposition of activation-
associated histone modifications and the localization of expression enhancing TFs. 
Functional domains behind both mechanisms can be fused to DNA binding domains 
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to locally increase gene expression at desired target sites, as described below. 
Whether this increase of expression and potential histone modification also increases 
accessibility for gene editing proteins is an area of active research (see Chapter 4). 
Significant progress towards reliable, targeted gene activation through 
epigenetic control has been made, but a few key factors remain to be fully 
addressed. Foremost is the difficulty of inducing sustained activation after transient 
interaction with an activator. In other words, full remodeling of the chromatin from 
heterochromatin to a sustainable (wider-reaching) euchromatin state is still a 
challenge. This may be due to several factors including the putative phase-separated 
nature of heterochromatin, which favors reformation of dense chromatin after slight 
disruption (Erdel and Rippe). Heterochromatin spreading may also be a contributing 
factor (Greenstein and Al-Sady). The performance of targeted activators themselves 
may also be chromatin context-dependent. For example, Cano-Rodriguez et al. found 
that the endogenous chromatin microenvironment inhibited a targeted histone 
methyltransferase (Cano-Rodriguez et al.). Systematic studies at target sites with 
thoroughly mapped chromatin features will need to be conducted to elucidate the 
sources of such context dependence. Finally, many natural mechanisms of chromatin 
opening are under-utilized by biological engineers. This work seeks to address that 
gap in research.  
 
1.1.3    Chromatin as a Barrier to Genome Editing 
 
Chromatin prevents gene-editing enzymes from stably engaging with their 
targets. Since their discovery in the 1970s, prokaryotic proteins that bind to specific 
DNA sequences and carry out site-specific DNA cleavage — e.g., Type II restriction 
endonucleases (Loenen et al.) — have inspired the development of customizable 
nuclease-based systems that cut and alter DNA sequences in living eukaryotic cells. 
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Among these is the newcomer Cas9. This genetic editing tool is particularly attractive 
because only a short (~20 base pair [bp]) single-stranded guide RNA (sgRNA) is 
required to direct the Cas9 endonuclease to a specific location in the genome. 
Synthetic biologists and cell engineers have designed many alternate CRISPR-Cas9 
systems that harness the highly specific and customizable binding properties of 
Cas9-sgRNA complexes.  
Cas9 binding and endonuclease activity can be disrupted by nucleosome 
occupancy in vitro and in vivo. (Hinz et al.; Isaac et al.; Horlbeck et al.) The link 
between chromatin inaccessibility and Cas9 inhibition has been made in murine 
embryonic stem cells (Wu et al.), human cancer cells (Chari et al.; R. M. Daer et al.) 
and even zebrafish (Danio rerio). While other nucleases such as TALEs may also be 
perturbed by heterochromatin (Bultmann et al.), Cas9-based systems show a 
pronounced variability in robustness across genomic loci in different eukaryotic 
models. Variability in Cas9 editing can be linked to variance in chromatin architecture 
across the genome (Singh et al.). The context-dependence of Cas9 editing must be 
overcome for Cas9 to be the broadly effective, flexible tool genomic engineers 
require. To this end, scientists have investigated CRISPR-Cas9 activity within 
chromatin to identify critical design parameters for editing efficiency.  
The primary design element of any CRISPR-Cas9 system is the sgRNA. In vivo 
studies have shown that sgRNA selection impacts editing efficiency in 
heterochromatin (R. M. Daer et al.; Uusi-Mäkelä et al.) and that sites with increased 
editing efficiency are often positively associated with areas of active transcription or 
open chromatin (Uusi-Mäkelä et al.). The distance between nucleosomes and the 
sgRNA recognition site has been shown to impact editing (Isaac et al.) — areas with 
high nucleosome occupancy are more likely to exhibit variability in editing across 
nearby target sites.  
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Cas9 protein concentration may also be an important parameter for improving 
editing in heterochromatin. Sampling of DNA binding sites by the Cas9-sgRNA 
complex is slowed in heterochromatin, suggesting that increasing protein 
concentration may increase sampling and successful binding events (Knight et al.). 
Likewise, editing is also delayed in heterochromatin in a concentration-dependent 
manner (Kallimasioti-Pazi et al.).  
A few attempts have been made to engineer the limited intrinsic chromatin-
opening ability of Cas9 proteins. Barkal et al. report that a catalytically dead Cas9 
(dCas9) can induce chromatin accessibility as measured by DNAse (i.e., a nuclease 
that degrades DNA) hypersensitivity and gene activation at 16 previously 
inaccessible genomic loci in mouse embryonic stem cells (mESCs) (Barkal et al.). 
However, previous work shows that Cas9’s ability to open chromatin is highly 
dependent on local chromatin structure, which was not investigated through either 
the interrogation of histone post-translational modifications (PTMs) or nucleosome 
positioning in Barkal et al. Their dCas9 system was also genomically integrated, 
possibly yielding higher dCas9 expression levels than by transient transfection. 
Another group, Chen et al., used SpCas9, derived from Streptococcus 
pyogenes, to assist in opening chromatin for FnCas9, a novel RNA-guided nuclease 
(Chen et al.). This approach targets multiple SpCas9s between 7 bp and 50 bp from 
FnCas9, presumably forcing open local chromatin (although alterations to chromatin 
structure were not determined in their study). This approach does improve FnCas9 
function, but the mechanism and efficacy across cell types and loci remains unclear. 
Although Cas9 design parameters can be manipulated in some contexts, inhibitory 
nucleosome occupancy remains an obstacle in many cases. Guide RNA target sites 
may be limited for certain applications and, although high concentrations of Cas9 
may be able to surmount chromatin inhibition (Kallimasioti-Pazi et al.), this may be 
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both difficult to achieve and undesirable in vivo, where the host immune response to 
Cas9 must be taken into account (Charlesworth et al.). We ultimately need to 
remodel local chromatin structure to reduce variability and increase efficiency of 
Cas9-mediated editing throughout the genome.  
 
1.2 Tools for Opening Chromatin 
 
Editing the epigenome in order to harness chromatin as another layer of 
control for eukaryotic gene expression is a topic of growing interest (Park et al.). 
While dynamic regulation of epigenetic state has been achieved (Bintu et al.; Park et 
al.) harnessing this ability to improve Cas9 function remains a nascent area of 
research. Earlier studies showing that nucleosomes inhibit Cas9, were also able to 
reverse this inhibition with chromatin remodelers known to displace nucleosomes, 
suggesting a mechanism for engineering Cas9-accessible chromatin (Isaac et al.; 
Horlbeck et al.). We have also tested targeted activators as a means of reversing 
chromatin inhibition of Cas9 (R. Daer et al.). Such targeted activators have already 
shown promise for selectively remodeling genomic structures (P. Liu et al.) in a more 
controlled manner than is possible with epigenetic drugs, which induce genome wide 
disruptions to chromatin structure rather than intentional changes at a specific locus. 
In vivo, the cell utilizes a suite of native mechanisms to carefully tune accessibility 
and expression in the dynamic chromatin environment. Here, I explore these 
mechanisms, previous attempts at harnessing these cellular mechanisms that may 
assist in engineering chromatin (Table 1.1) and their potential to induce Cas9-
accessible chromatin states. The next sections describe the native mechanisms of 
chromatin opening (Figure 1.2),previous attempts at harnessing these cellular 
mechanisms that may assist in engineering chromatin (Table 1.1), and their 
potential to generate Cas9-accessible chromatin states 
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1.2.1 Direct Histone Modifiers as Chromatin Opening Tools 
 
For many TFs an exposed DNA consensus sequence is not sufficient to initiate 
binding in chromatin; posttranslational histone modifications (PTMs) work in concert 
with TFs to open chromatin (Guertin and Lis). Certain combinations of 
posttranslational histone modifications promote an accessible chromatin state as 
characterized by increased DNAse accessibility and actively transcribed genes 
(Bannister and Kouzarides). Previous work has shown the efficacy of engineered 
Direct Histone Modifying proteins (DHMs) for inducing an active, accessible 
chromatin state at a specific genomic target site (Figure 1.2a) (de Groote et al.). 
 
1.2.1.1 Targeted Histone Methylases and Acetylases 
 
 Two major classes of DHMs have been engineered to date: histone 
methyltransferases and histone acetyltransferases. Both directly modify the histone 
tails of nucleosomes thereby altering local charge interactions that may disrupt 
histone-DNA binding interactions. They also serve as chemical marks to recruit 
transcription factors and other chromatin remodeling machinery. By fusing histone-
modifying domains to DNA binding domains, targeted epigenetic manipulation can be 
achieved. 
 A variety of targeted DHMs have been used to modify local histone 
methylation. A few targeted demethylases have been engineered to deplete 
repressive histone methylation marks (Yokoyama et al.; Fukushige et al.). A fusion 
of histone demethylase KIAA1718 to a Gal4 DNA binding domain increased 
expression through the depletion of repressive histone methylation. (Yokoyama et 
al.) Depletion of these repressive marks is most likely directly responsible for 
induction of an active state by KIAA1718, as mutant KIAA1718 lacking 
demethylation activity does not enhance transcription (C. Huang et al.). Along with 
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histone methylation erasers, histone methylation writers have also been engineered 
to open chromatin. Several groups (Table 1.1) have developed targeted histone 
methylases capable of increasing local expression and adding active histone 
modifications (Stulemeijer et al.; Okada et al.; Cano-Rodriguez et al.; Hayashi et 
al.). 
 Histone acetyltransferases have also been used to engineer targeted DHMs. 
Several groups have effectively used fusions of EP300 to both LexA and dCas9 to 
increase local expression and deposit H3K27ac at promoter regions, which precludes 
the deposition of repression-associated H3K27me (Kwaks et al.; Hilton et al.). A 
variety of other histone acetyltransferase DHMs have been engineered to modulate 
expression state and modify local chromatin both in vivo and in situ (Krumm et al.; 
Martinez-Balbas; Santillan et al.). 
 
1.2.1.2 Histone Modification Crosstalk Impacts DHM Function  
 
Histone modifications display a certain level of crosstalk (Fischle et al.). 
Certain modifications may only be deposited if other modifications are pre-existing 
on the histone tail (Fischle et al.; McGinty et al.). The complexity of histone 
modification crosstalk is an important design parameter to consider when 
engineering open chromatin. For example, Cano-Rodriguez et al. found the 
chromatin microenvironment of their target sites, specifically levels of DNA 
methylation, impacted the ability of their DHM to deposit H3K4me and induce 
activation. Furthermore, H3K79me co-localization appeared to assist in stability of 
H3K4me transmission. Histone modification co-dependence has been shown for other 
engineered DHM domains as well (McGinty et al.; O’Geen et al.). 
While silencing can be reversed using targeted histone modifications, doing so 
in a heritable manner that does not required the continued action of DHMs remains a 
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challenge. Persistence of open chromatin may be useful for engineering stable cell 
lines or for using Cas9 at low concentrations and thus a slow sampling rate. Several 
groups have managed to achieve this over a few generations of cell doubling 
(Kramer et al.), although persistence of activation may, again, be dependent on the 
co-localization of other histone modifications (Cano-Rodriguez et al.; Rivenbark et 
al.; X. Xu et al.). 
 
1.2.2 Targeted Transcriptional Activation Domains 
 
Although direct histone modification may encourage an increase in expression 
and directly alter chromatin structure, targeted recruitment of activating 
transcription factors has been a more popular approach for inducing strong increases 
in expression (Figure 1.2b). Two domains have been particularly well studied- Herpes 
simplex virus protein vmw65 (VP16) and nuclear factor NF-kappa-B p65 subunit 
(p65) encoded by the human RELA gene. VP16 subunits can be effectively fused 
together (i.e. VP64, VP160, etc.) along with a DNA binding domain to induce an 
increase in expression (Table 1.1) (Cheng et al.; Polstein et al.; Perez-Pinera, 
Ousterout, et al.; Tanenbaum et al.). While many studies show that VP16-based 
systems are able to increase expression across biological systems, few have looked 
at its structural impact on chromatin. Two independent groups have shown that 
VP64-dCas9 recruits remodeling factors and has been linked to increased chromatin 
accessibility and to the deposition of activating histone marks, including H3K27ac 
and H3K4me (Black et al.; Konermann, Brigham, A. E. Trevino, et al.). More wide 
scale effects that may increase accessibility such as nucleosome depletion have not 
been investigated.  
 P65 based systems have been harnessed in combination with VP64 by several 
groups to induce high levels of activation necessary to reprogram cells (Y. Zhang et 
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al.). However, p65-based systems have an undetermined effect on chromatin 
structure and accessibility. Some research suggests that excessive levels of 
transcription such as those induced by p65 may initially inhibit Cas9 editing due to 
Polymerase crowding (Clarke et al.; R. Daer et al.). Thus, when engineering 
accessibility with activators it may thus be important to consider their broader effect 
on the local chromatin environment. Histone modifications as well may not  
always be enough to induce an accessible state. Therefore, we propose two under-
explored but promising strategies that leverage other endogenous tools for 
chromatin opening. 
 
1.2.3 Canonical Pioneer Factors 
 
Pioneer factors (PFs) are a unique class of non-enzymatic transcription factors 
able to bind DNA in heterochromatin and initiate the transition to an open state 
without the use of ATP or other cofactors (Figure 1.2c) (Zaret and Carroll). They 
engage sterically hindered DNA (that is bound to nucleosomes) by disrupting 
histone-DNA binding (Zaret and Carroll). PFs are crucial to cell development and 
reprogramming, serving as the initial foot-in-the-door for other TFs and DNA binding 
proteins (Iwafuchi-Doi and Zaret). While PFs have not been extensively investigated 
or manipulated as fusion protein tools, this well-characterized and highly conserved 
class of proteins has the potential to be tapped as a new resource for genomic 
engineering. 
 
1.2.3.1 Structure and Function of Canonical Pioneer Factors 
 
 Pioneer factors begin the cellular cascade that transitions a heterochromatic 
locus to an open state of active transcription (Zaret and Carroll). PFs are unique in 
their ability to directly bind DNA bound to nucleosomes for a stable period before 
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activation and before other factors are recruited, imparting the necessary 
competence to initiate an open state (Zaret and Carroll). This transition initiation 
function is crucial to the dynamic regulation of the eukaryotic genome and is thus 
well conserved. Yeast Gal4 usurps endogenous chromatin remodelers through DNA-
binding in order to displace histones at promoters and activate transcription (Kang et 
al.; Owen-Hughes and Workman). PFs are vital in initiating differentiation during the 
development process in both Drosophila and humans as well (Nien et al.; Liang et 
al.; Foygel et al.; Pan and Schultz). Iwafuchi-Doi and Zaret provide a useful 
compendium of verified pioneer factors across species, although more and more PFs 
are still being discovered (Oldfield et al.; Iwafuchi-Doi and Zaret). 
 Of these validated pioneer factors, Forkhead box protein A1 (FoxA1) is by far 
the most well-studied. It’s structure and mechanism of nucleosome displacement 
serve as a model for general PF function. Early research on FoxA1 showed that the 
purified protein was able to bind target sites on nucleosomal DNA in a non-ATP 
dependent manner, opening previously closed areas of chromatin through the 
displacement of nucleosomes (Cirillo et al.). How is FoxA1 able to exert this type of 
remodeling power without catalytic energy expenditure? Further research showed 
that FoxA1 in fact has a preference for binding in nucleosome occupied sites as 
opposed to most TFs, which are inhibited by nucleosomes (Z. Li et al.). Indeed, 
FoxA1 binds quite tightly as indicated by its slow movement in chromatin and binds 
without the need for any histone PTMs (Sekiya et al.).  
This unusual affinity between a TF and nucleosomes is partially revealed in 
the crystal structure of FOXA1, which has a winged helix motif with high homology to 
the DNA binding domain of linker histones H1 and H5 that also bind nucleosomes 
with great affinity (Clark et al.; Cirillo et al.). Linker histones favor chromatin 
compaction by contorting linker DNA and bringing distant nucleosomes into contact 
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(Cirillo et al.). FoxA’s winged helix motif, however, has a slightly higher binding 
affinity to DNA than linker histones, allowing the protein to displace them by (Cirillo 
et al.). This winged helix motif binds the DNA helix along the long axis, leaving the 
other side still bound to core histones (Clark et al.).  By binding simultaneously to 
the DNA and the core histones, FoxA1 disrupts local internucleosomal interactions 
between linker histones and the nucleosome core that stabilize chromatin higher-
order structure (Schalch et al.; Lisa Ann Cirillo et al.). This disruption of condensed 
chromatin structures enhances accessibility, allowing other transcription factors to 
bind and stimulate transcription (Iwafuchi-Doi et al.). Through this mechanism, PFs 
can also bookmark enhancer regions putting them in a poised state by loosening 
chromatin and preventing the deposition of repressive histone modifications by 
occupying potential histone modifier binding sites (Cirillo et al.).  
 
1.2.3.2 Pioneer Factors in the Complex Chromatin Environment 
 
Pioneer factors interact dynamically with chromatin, both by shifting 
nucleosomes and through the occupation of potential chromatin effector binding sites 
(Zaret and Carroll; Cirillo et al.). PFs are impacted chromatin in several ways. Firstly, 
the are uniquely attracted to nucleosomes, running contrary to the dogma that 
nucleosomes are exclusively repressive as dense nucleosome occupancy at enhancer 
regions may stimulate PF recruitment (Barozzi et al.). PFs also interact with histone 
PTMS and other chromatin modifications such as DNA methylation, which is known to 
decrease FoxA1 binding (Sérandour et al.). Other histone PTMs are known to inhibit 
the PF function, such as inhibition of Oct3/4, Sox2, and Klf4 by H3K9me during 
fibroblast differentiation (Soufi et al.). Reducing the presence of H3K9me allows 
remodeling by these PFs to continue, adding another layer of control to the cellular 
reprogramming process of which PFs are an integral part (Soufi et al.). Enrichment of 
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H3K9me2 is also negatively associated with FoxA1 recruitment, further highlighting 
the need to consider the larger chromatin environment when engineering open states 
(Lupien et al.). 
PFs also exert an influence on chromatin structure and histone modifications. 
H3K9ac deposition follows or may be concomitant with FoxA1 binding, opposing any 
deposition of repressive H3K9me (Taube et al.). Other activation-associated 
modifications such as H3K4me are also associated with PF binding at enhancers 
(Sérandour et al.; Lupien et al.; Heinz et al.). Deposition of such modifications, 
coupled with linker histone displacement further serves to bookmark enhancer 
regions and prevent repressive modifications, potentially allowing for a longer-term 
open chromatin state (J. Xu et al.; You et al.). 
 
1.2.3.3 Pioneer Factors as Tools for Engineering Open Chromatin 
 
While human PFs have to date not been engineered as DNA-binding protein 
fusions, the idea has been put forth by previous reviewers of the topic: “Conceivably, 
such chromatin-opening domains could be transferred to other factors and augment 
their regulatory function” (Zaret and Carroll). Yeast pioneer factor Gal4 has been 
extensively used in engineering, but primarily for its DNA binding domain. Erkine and 
Gross have shown that its histone binding domain in isolation does deplete histones 
at a target site, giving a precedence for isolating PF functional groups for engineering 
(Erkine and Gross). Other PF functional domains such as the winged-helix domain of 
FOXA1 have been identified (Cirillo et al.) providing us a tool kit to begin working 
with and targeting to loci of interest with DNA binding domains. Indeed previous 
work suggests that continuous FOXA PF binding is not required to maintain local 
nucleosome organization (X.-Y. Li et al.; Thomassin et al.) or in other words that we 
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can produce a primed chromatin state with only a transient induction, leaving the 
site open for Cas9.  
 
1.2.4 ATP-Dependent Chromatin Remodelers 
 
Chromatin remodelers (CRs) exert a powerful effect on chromatin structure 
by directly displacing nucleosomes in a reaction driven by ATP. Unlike PFs, the 
displacement of nucleosomes by CRs is driven by an ATP-dependent process that is 
currently still the subject of debate, as opposed to energetically favored structural 
binding (Figure 1.2d).  
 
1.2.4.1 Structure and Function of ATP-Dependent Remodelers 
 
CRs are typically large multi-subunit complexes, powered by an ATP-
hydrolysis motor, that shift, remove, or exchange nucleosomes from DNA (Clapier et 
al.). Together with sequence‐specific TFs CRs orchestrate the precise positioning of 
nucleosomes in eukaryotic genomes (Clapier et al.; Bowman and McKnight). While 
the ATP-hydrolysis motor is a common function among CRs their effects on 
nucleosome positioning differ drastically (Hota and Bartholomew). For example, in 
the switch/sucrose non-fermentable (SWI/SNF) system, the ATPase motor’s helicase 
motif binds to nucleosomal DNA, disrupting histone DNA binding, while auxiliary 
subunits bind to superhelical structures to act as a counter grip for the motor to 
displace nucleosomes (X. Liu et al.). While some CRs remove nucleosomes, others 
slide nucleosomes along the DNA (Figure 1.3). For example, ISWI remodelers pull 
DNA through the nucleosome and out of the exit site during remodeling (Deindl et 
al.). Still others exchange histones of the nucleosome for new histone varieties 
(Figure 1.3) (Narlikar et al.). While the exact mechanism that drives the ATPase 
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motor is still debated, the structural evidence that does exist for CRs suggests a 
series of distinct subunits associate with unique functions open to isolation and 
engineering. Although the exact mechanism that drives the ATPase motor is still 
debated, evidence suggests that distinct subunits are associated with unique 
functions that can be isolated and engineered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Potential outcomes of ATP-Dependent chromatin remodeling. ATP-
dependent chromatin remodeling complexes (in yellow) catalyze a reaction that can 
result in several outcomes. Nucleosomes may be locally depleted through removal or 
by sliding them along the DNA strand. The physical structure of the local chromatin 
can also be disrupted by remodeling of the nucleosome-DNA interaction or the 
physical exchange of nucleosomes to alternate histone variants that are more 
permissive to a euchromatin state. 
 
 
1.2.4.2 Nucleosome Remodelers as Tools for Opening Chromatin 
 
Pioneering efforts have been made to stimulate chromatin remodeling at 
targeted sites. Keung et al, who screened a library of 223 yeast chromatin-regulating 
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domains (many of which were remodelers) fused to a DNA binding domain to 
determine their relative effects on expression (Keung et al.). They identified a large 
number of domains that successfully increased expression at the target locus. 
McKnight et al fused the nucleosome sliding domain Chd1 to a yeast DNA binding 
domain, representing one of the few successful examples of engineered sequence-
targeted remodeling (McKnight, Tsukiyama, et al.). Their targeted remodeler 
successfully added nucleosomes to the target site, inducing a closed chromatin state. 
These works serves as a proof of concept for engineering chromatin states with CRs.  
While McKnight et al. demonstrated gene repression in their CHD1-based 
system, theoretically this directional sliding remodeler could also induce an open 
state by pushing nucleosomes further downstream away from the promoter (Table 
1.1). This is often its native function; in mouse embryonic fibroblasts Chd1 evicts 
nucleosomes from promoters to allow for PolII entry into the site, providing a 
precedence for this domain to induce an open state that may facilitate an open state 
amenable to editing (Skene et al.). CRs such as CHD1 could be used to expose DNA 
to Cas9 for genome editing, because CRs do not directly initiate transcription but 
instead physically open chromatin. CHD1 has been shown to detach two turns of 
DNA from the nucleosome as it positions its ATP-driven motor for catalysis, 
suggesting a loosening, as well as a nucleosome-sliding function (Farnung et al.). 
Braun et al. have also achieved targeted activation with chromatin 
remodelers, although not through the construction of direction fusions (Braun et al.). 
Instead, they utilize a dCas9-MS2 anchor system by which they can induce the 
recruitment of the SWI/SNF (BAF) chromatin remodeling complex to a specific site. 
While they did not examine the effects of recruitment on nucleosome positioning, 
they did see increases in transcription as well as effective Polycomb Repressive 
Complex II (PRC2) antagonism as shown by the deposition of activating H3K4me3 
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marks and the depletion of H3K27me3 typically deposited by PRC2. Although 
activation via this system proved to be transient, this study is unique in its inducible 
mechanism for targeted remodeling. 
 Can we separate these useful functions of loosening DNA and sliding 
nucleosomes to be individual tools for chromatin opening? Many remodelers systems 
including Chd1 and ISW complexes have HAND-SANT-SLIDE domains with more 
distinct known functionality. The architecture of the HAND-SANT domains suggests 
their involvement in a loosening mechanism whereby DNA is pushed into the 
nucleosome entry site to move it circum the nucleosome (Dang and Bartholomew). 
Interestingly, SANT-SLIDE deletion removes directionality of nucleosome sliding, 
suggesting an involvement in sliding (McKnight, Jenkins, et al.). Deletion of all three 
of these domains reduces rates of remodeling drastically, suggesting their functions 
greatly aid the ATPase-motor in remodeling (Mueller-Planitz et al.). 
 While the domains of interest explored above effectively remodel local 
chromatin, few have attempted broad scale disruption of higher-order chromatin 
structure with a sequence-specific fusion (Table 1.1). Although this approach may be 
too disruptive for many applications, it may be useful when targeting Cas9 to several 
loci across an entire gene. Deng et al achieved this sort of large scale remodeling by 
fusing the Lbd1 domain with a DNA binding domain (Deng et al.). Lbd1 forced 
contact between the targeted promoter and upstream enhancer regions to activate 
transcription. This type of long-distance remodeling and activation may be useful to 
disrupt board areas of dense heterochromatin that inhibit editing across an entire 
coding sequence. 
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1.3 Innovations in Chromatin Opening 
 
Cells use several mechanisms in concert to regulate the opening and closing 
of chromatin. Though progress has been made toward engineering each of these 
mechanisms in isolation, synergistic approaches may be able to more effectively tune 
chromatin states. How do we begin to design strategies to open chromatin that 
harmoniously and effectively use multiple chromatin effectors? Can we do this in a 
manner that decouples opening from increases in expression that may preclude 
effective editing? To do so would support efficient editing across the genome without 
inducing pleiotropic effects on metabolism and regulation.  
 
1.3.1 Effectively Combining Chromatin Opening Strategies 
 
One of the challenges in designing robust and reliable chromatin remodeling 
is crosstalk between different remodeling activities. For instance, histone 
modifications can alter the chromatin landscape in ways that promote or inhibit the 
function of CRs. Therefore, it is important to consider the synergistic or inhibitory 
relationship between different chromatin features. Cooperative interactions that drive 
the opening of chromatin suggest the potential for engineering effective systems to 
expose DNA to nuclease-mediated sequence editing. 
 The targeted deposition of histone modification has been successfully 
engineered on several occasions, suggesting it as a relatively easy strategy to use in 
concert with other mechanisms of chromatin opening. For example, through frequent 
transient interactions, CRs scan the biophysical potential of nucleosomes to be 
displaced. Most of these encounters do not lead to remodeling; the outcome of the 
interaction depends on increased binding affinity to chromatin that is mediated 
through histone PTMs and the colocalization of PFs (Erdel et al.). Histone acetylation 
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typically precedes chromatin remodeling, therefore DHMs (such as p300) can 
prepare a target site for remodeling (Huang et al.; Chatterjee et al.).  
 Activators have also been successfully used in concert with native remodeling 
machinery. VP16 interacts with the SWI/SNF complex to promote transcription 
(Neely et al.). This relationship was leveraged by Gutiérrez et al, who targeted a 
Gal4_VP16 fusion to a target site in order to recruit SWI/SNF and induce remodeling 
(Gutiérrez et al.). This approach has been validated for other CRs as well; VP16 and 
INO80 work in concert to enhance chromatin mobility and remodeling (Neumann et 
al.).  
There is also some evidence that suggests the utility of PFs in assisting in 
remodeling. PFs assist in readying chromatin for transcription and remodeling. Linker 
histone H1 inhibits the activity of certain CRs (Hill and Imbalzano). PFs such as 
FoxA1 can directly displace H1, providing a mechanism by which PFs and CRs may 
be used in sequence to engineer an accessible chromatin state.  
Synergistic strategies may also help overcome expansive heterochromatin 
environments that are spread over several kilobases of inter- and intra-chromosomal 
neighborhoods. Multi-dimensional chromatin structures are regulated by 
combinations of factors that affect accessibility, suggesting the need for a 
combination of factors to disrupt these structures (Buenrostro et al.). For example, 
the regulation of boundaries between open and closed chromatin relies on both 
histone PTMs and nucleosome arrangement (Chai et al.). Moreover, these boundaries 
can be highly distinct, forming liquid-like compartments through mechanisms akin to 
phase separation making them difficult to disrupt (Erdel and Rippe). In vitro 
evidence suggests that differences in nucleosome density (as regulated by PTMS, PF 
presence, etc.) contribute to phase separation (Yamamoto and Schiessel). Due to the 
expansive, dense nature of these liquid-like compartments combinatorial approaches 
  26 
to opening may be necessary. Native regulation of these liquid-like compartments 
relies of interactions between CRs and siRNAs, suggesting avenues of exploration for 
combinatorial engineering of large-scale heterochromatin disruption (Wan et al.). 
 
 
1.3.2 Decoupling Chromatin Remodeling from Expression 
 
Structural opening of chromatin and the initiation of transcription are two 
distinct events, yet their occurrence are often linked. This may present an issue 
when we wish to engineer a chromatin state that increases accessibility to genetic 
editing machinery. An increase in transcription may not be a desirable outcome for 
engineered cells. Whether knocking out a gene with an undesirable gene product or 
editing a region that is associated with large-scale effects on cellular function, care 
must be taken to expose rather than activate DNA. Additionally, high levels of 
transcription may actually inhibit editing. Recent evidence suggests that Pol II 
(associated with high levels of transcription) physically displaces SpCas9 
endonucleases (Clarke et al.). This is consistent with work showing that the use of 
p65 activators, which recruit Pol II, may initially inhibit rather than enhance editing, 
even if chromatin is being opened (R. Daer et al.).  
 How then can we decouple opening from enhancement? Is there an accessible 
intermediate state between closed and active chromatin? Research suggests that a 
“poised” state may strike a balance between chromatin closure and active 
transcription. This Goldilocks state is characterized by the colocalization of opposing 
factors such as repressive and active histone PTMs, repressive histone marks with 
PFs, or repressive proteins and transcription factors (Sérandour et al.). For example, 
FOXA1 depletes local nucleosomes and recruits other nuclear proteins to establish a 
poised expression-competent state (Zaret and Carroll). The threshold for activation 
  27 
of the gene is now much lower; with nucleosomes already removed from the DNA, 
only the displacement of a few repressors is necessary to induce activation. This less 
dense, easily activated state developed by FOXA1, makes the gene poised for 
activation. Likewise, specific combinations of activation associated PTMs can push a 
state from poised to active (Creyghton et al.). Deposition of histone PTMs may, if 
carefully designed, also be able to induce a poised state without increases in 
expression.  
Chromatin is a dynamic, DNA-shielding barrier that is natively regulated by a 
host of mechanisms. These mechanisms are not beyond our control and may be 
engineered to specifically target genomic areas of interest to increase the 
effectiveness of genetic editing. The interplay of these many epigenetic mechanisms 
suggests that synthetic multimodal systems may be the key to gaining complete 
access to eukaryotic DNA for genome engineering. 
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CHAPTER 2 
 
USE OF MYB AS A NEW SYNTHETIC ACTIVATOR TO ENHANCE TRANSGENE 
EXPRESSION WITHIN REPRESSED POLYCOMB CHROMATIN☨ 
 
Epigenetic silencing of transgenes through chromatin packaging has been a 
persistent issue for the development of transgenic mammalian cell lines. Endogenous 
mechanisms are known to induce a closed chromatin state around foreign DNA 
before and after it has been integrated into a host cell’s genome. Scientists are 
interested in reversing this silencing, but a lack of a priori knowledge of the 
chromatin features at transgenes hinders the rational design and application of 
effective strategies for transcriptional activation. Here, we systematically tested 
activation-associated DNA elements and proteins in transfected plasmid DNA and at 
epigenetically silenced chromosomal transgenes. We demonstrated that placing DNA 
elements that are targeted by MYB (c-myb) and p65 upstream of a minimal 
promoter enhance expression from transfected plasmid DNA. To regulate the 
expression of chromosomally integrated transgenes, we used proteins fused to the 
Gal4 DNA binding domain or dCas9/sgRNA. Three activation-associated peptides, 
p65, VP64, and MYB, sustained reactivation of transgene expression over 15 cell 
divisions in an immortalized human cell line (HEK293). Activity of the MYB fusion was 
inhibited by celastrol, a drug that blocks interactions between MYB and the p300/CBP 
histone acetyltransferase complex. Single-site targeting via dCas9-MYB was sufficient 
____________________________________ 
☨This chapter is a manuscript under review. See Appendix D for permissions and authorships. 
Pre-print citation: Barrett, Cassandra M., et al. Use of MYB as a New Synthetic Activator to 
Enhance Transgene Expression within Repressed Polycomb Chromatin. doi:10.1101/487736. 
 
  39 
to activate transgenes within ectopic Polycomb heterochromatin and at a different 
site that had undergone position effect silencing. We demonstrate the utility and 
flexibility of cis-regulatory elements and fusion proteins derived from natural gene 
regulation systems to enhance expression from epigenetically silenced transgenes. 
DNA motifs for p65 and MYB can be added to the transgene itself, or the activating 
proteins can be targeted to transgenes without enhancers to stimulate gene 
activation. This work has implications for determining the most appropriate strategy 
to enhance gene expression specifically in Polycomb-repressed chromatin. 
 
Figure 2.0: Targeted enhancers can be used to reverse transgene silencing. After the 
delivery of transgenic material into the cell, transgenes can either be stably 
integrated or maintained in the cell as plasmids. In both scenarios, heterochromatin 
may form around the transgenic material as a natural defense mechanism against 
foreign (viral) DNA. This accumulation of nucleosomes and repressive proteins 
prohibits active gene expression. To reverse this in a targeted manner, two general 
approaches can be used. DNA sequences that recruit enhancers may be integrated 
into the original construct. Here we test several mammalian enhancers on plasmid 
DNA to compare their ability to increase expression of plasmid-borne transgenes. 
Alternatively, DNA sequence-specific fusion proteins with activation-associated 
domains may be able to reverse silencing of chromosomally integrated transgenes.  
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2.1 Background 
 
The advancement of cell engineering requires robust and reliable control of 
endogenous and synthetic genetic material within living cells. A lack of tools for 
enhancing the expression of transgenes in mammalian cells currently limits effective 
gene regulation across contexts. The rapid formation of heterochromatin around 
transgenic material in mammalian cells limits our ability to express foreign DNA for 
the production of therapeutic proteins and the development of engineered 
mammalian systems for biosensing and computing (Brooks et al.; Suzuki et al.). 
Integrated transgenes are often silenced by the same mechanisms that serve as a 
cellular defense against viral insertion into the genome (Leung and Lorincz; Ross et 
al.; Ellis). Nucleation of heterochromatin around transgenic material can be initiated 
and sustained by both promoter methylation (Brooks et al.; Ellis) and various histone 
modifications (Ross et al.; Suzuki et al.). For example, MyD88 pathway-mediated 
silencing of transgenes leads to an accumulation of repressive H3K9me on newly 
bound histones (Suzuki et al.; Gong et al.). Silencing of transgenes may also be 
Polycomb-mediated, where Polycomb repressive complexes deposit H3K27me3 on 
histones to establish a silenced state (Erhardt et al.; Dufourt et al.; Otte and Kwaks). 
The diversity and persistence of transgene silencing has led to the development of 
tools for mammalian cell engineering specifically aimed at combating 
heterochromatin. 
Recruiting activators to a specific locus in order to reverse epigenetic silencing 
can be achieved either by including an activation-associated cis-regulatory DNA 
sequence within the construct itself, or through the targeting of engineered fusion 
proteins to the silenced transgene. Both natural and synthetic cis-regulatory motifs 
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that recruit activators have been used (Johansen et al.; Cheng and Alper; 
Zimmerman et al.; Wen Wang et al.) to help increase transgene expression as an 
alternative to viral promoters that are prone to methylation and silencing (Brooks et 
al.). Previous screens by ourselves and other groups (Roberts et al.; Saxena et al.; 
Cheng and Alper) have identified mammalian activation-associated cis-regulatory 
elements that recruit endogenous factors to increase the expression of epigenetically 
silenced transgenes, including motifs for nuclear factor Y, CTCF, and elongation 
factor alpha (EF1-ɑ) (Zimmerman et al.; Wen Wang et al.). The underlying 
regulatory mechanisms are not entirely understood, since in this case efficient 
screening for functional sequences has been prioritized over dissecting the 
mechanism of individual elements.  
Fusion proteins that target activation-associated domains to transgenes can 
also be used to reverse silencing. Targeted activators such as VPR, SAM, and SunTag 
(Chavez et al.; Konermann et al.; Y.-H. Huang et al.) are composed of transcriptional 
activation domain (TAD) peptides, including Herpes simplex virus protein vmw65 
(VP16) and nuclear factor NF-kappa-B p65 subunit (p65). Site-specific targeting of 
VP64 (4x VP16) has been used to increase endogenous gene expression, and 
remodels chromatin through the accumulation of activation-associated histone 
modifications (H3K27ac and H3K4me) (Konermann et al.; Black et al.; Gao et al.). 
Likewise, p65-based systems are very effective at restoring both endogenous 
(Chavez et al.; Zhang et al.) and transgenic (Daer et al.) gene expression, but have 
an undetermined effect on chromatin structure and accessibility.  
Significant progress towards transgene reactivation has been made so far, but 
several important gaps remain. First, several natural mechanisms of activation are 
still under-investigated by biological engineers. For instance, chromatin remodelers 
shift, remove, or exchange nucleosomes (Clapier et al.), and pioneer factors increase 
  42 
DNA accessibility in closed chromatin by displacing linker histones (Clapier et al.; 
Zaret and Carroll; Magnani et al.). Second, the parameters for stable transgene 
activation are not yet fully defined. So far, at least two studies have demonstrated 
prolonged enhancement of transgenes (10 to 25 days) via targeted fusion proteins 
alone (Kramer et al.) or in combination with flanking anti-repressor DNA elements 
(Kwaks et al.). Neither study evaluated the chromatin features at the target genes 
prior to their reactivation, therefore the context in which expression enhancement 
occurred is uncertain. Finally, the performance of targeted activators can be context-
dependent. Catalytic domains used for site-specific chromatin remodeling (Santillan 
et al.; Hilton et al.; Kwaks et al.), may be inhibited by pre-existing chromatin 
features that vary across loci. For example, Cano-Rodriguez et al. constructed a 
targeted histone methyltransferase fusion and found that the endogenous chromatin 
microenvironment, including DNA methylation and H3K79me, impacted the ability of 
their fusion to deposit H3K4me and induce activation (Cano-Rodriguez et al.). 
Similarly inconsistent performance has been shown for other fusions that generate 
H3K79me and H3K9me (McGinty et al.; O’Geen et al.). Systematic studies at loci 
with well-defined chromatin compositions are needed to fully understand 
mechanisms of chromatin state switching.  
 Here, we expand previous work where we had identified cis-regulatory 
sequences that enhanced expression from plasmid-borne transgenes (Zimmerman et 
al.). To regulate expression of chromosomally inserted transgenes, we compare 
targeted proteins that represent diverse activities: transcriptional activation through 
cofactor recruitment, direct histone modification, and nucleosome repositioning and 
displacement. We focus on reversal of silencing within Polycomb heterochromatin, 
which is known to accumulate at transgenes that are integrated into chromosomes 
(Erhardt et al.; Dufourt et al.; Otte and Kwaks) and is widely distributed across 
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hundreds or thousands of endogenous mammalian genes that play critical roles in 
normal development and disease (Otte and Kwaks; Aloia et al.; Poynter and 
Kadoch). We report that recruitment of p65 and MYB-associated components via a 
cis-regulatory element or fusion proteins enhances expression from epigenetically 
silenced transgenes. MYB-mediated activation within Polycomb heterochromatin 
relies on interactions with p300 and CBP. Our results have implications for 
determining the most appropriate strategy to enhance gene expression, specifically 
within Polycomb-repressed chromatin. 
 
2.2 Results 
 
2.2.1 Identification of Activation Associated Peptides 
 
We surveyed public data to identify epigenetic enzymes and other proteins 
that are associated with transcriptional activation, and therefore might effectively 
disrupt repressive Polycomb chromatin. Polycomb-enriched chromatin typically 
includes Polycomb Repressive Complex 1 (PRC1: RING1A/B, PCGF1–PCGF6, CBX2, 
PHC1–PHC3, and SCMH1/2) (Schuettengruber et al.), PRC2 (EZH1/2, EED, Suz12, 
and RBBP4/7) (Schuettengruber et al.), H3K27me3, histone deacetylation, 
H2AK119ub1, and lncRNAs (Simon and Kingston; Schuettengruber et al.). Each 
activation-associated peptide (AAP) generates modifications of histone tails either by 
intrinsic catalytic activity or the recruitment of chromatin-modifying co-factors. In 
order to predict how these AAPs might influence Polycomb heterochromatin, we 
searched the STRING protein-protein interaction database for binding partners and 
their associated chromatin-modifying activities (Figure 2.1). 
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 The AAPs fall into six general categories. The transcriptional activation group, 
(NFkB)-p65 and the MYB (c-myb) transcriptional activation domain (TAD), includes 
proteins that recruit RNA Polymerase II (PolII) and p300/CBP, respectively. These 
AAPs have no known intrinsic gene regulation activity, and therefore rely upon the 
recruitment of other proteins to stimulate transcription (Beerli et al.; P. Q. Liu et al.; 
Weston and Michael Bishop). We also included the recombinant TAD VP64 (four 
tandem copies of VP16), a popular component for synthetic activators. Histone 
modifications deposited by the co-activators that are recruited by these three 
domains are primarily associated with activation.  
The histone acetylation (HAT) group includes ATF2, P300, and KAT2B. These 
peptides acetylate H3K27. In particular, p300 is associated with the recruitment of 
CBP and other co-activators that generate the activation associated mark H3K4me 
(Vo and Goodman). The histone H3 methyltransferase (H3 MT) group and the H4 
methyltransferase (H4 MT) group include proteins that are either Mixed-Lineage 
Leukemia (MLL) complex components or SET proteins. SETD7 deposits the 
activation-associated modification H3K4me, but its regulatory impact may vary 
based on local DNA methylation, which can enhance or impede co-recruitment of 
repressive cofactors. The histone H4 methyltransferase PRMT5 induces histone 
acetylation that is associated with DNA methylation in some contexts (Zhao et al.). 
Still, PRMT5 primarily acts as an activator. 
The final two groups, chromatin remodelers (CR) and pioneer factors (PF) 
represent activities that are relatively underexplored in the design of fusion-protein 
regulators. SMARCA4 is a chromatin remodeler that relies on an ATP-dependent 
reaction to shift the position of nucleosomes at a target site (Antonysamy et al.). It 
does not mediate the deposition of histone modifications, but is associated with CBP 
recruitment that evicts Polycomb-associated histone modifications (Alver et al.). PFs 
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are represented in our library by FOXA1, a winged-helix protein that displaces linker 
histones from DNA to facilitate a transition to open chromatin (Clark et al.). In 
general, PFs bind to DNA within heterochromatin and do not catalyze histone post-
translational modifications (Magnani et al.). 
Several of the AAPs in our panel are associated with the eviction of Polycomb 
repressive complexes (PRCs) from endogenous genes. Accumulation of the 
chromatin remodeling protein SMARCA4 (BRG1) leads to the loss of PRCs at Pou5f1 
in mouse cells (Kadoch et al.) and at INK4b-ARF-INK4a in human malignant rhabdoid 
tumor cells (Kia et al.). In the latter case, KMT2A (MLL1) also participates in PRC 
depletion. ATF2 interacts with a kinase that generates H3S28p, which antagonizes 
PRC binding (Lau and Cheung; Gehani et al.; Josefowicz et al.). Acetylation and 
methylation at H3K27 are mutually exclusive (Tie et al.; Englert et al.), therefore the 
AAPs associated with H3K27ac (p65, MYB, ATF2, P300, KAT2B) might contribute to 
PRC eviction (Figure 2.1). None of the AAPs in our panel are associated with 
enzymatic erasure of H3K27me3. 
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Figure 2.1: Activation-associated histone modifications associated with activation-
associated peptides (AAPs) used in this study. Interaction partners determined by 
STRING analysis are listed in Appendix A, Table A1. Previous work that characterized 
each AAP is cited in Appendix A, Table A2. H3 MT = histone H3 methyltransferase, 
H4 MT = histone H4 methyltransferase, CR = chromatin remodeler, PF = pioneer 
factor, PE = Polycomb eviction, A = transcriptional activation. 
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2.2.2 Cis-regulatory elements recognized by transcriptional activators p65 and MYB 
enhance expression from an extra-chromosomal transgene  
 
First, we used enhancer DNA elements to regulate expression from transiently 
transfected plasmid DNA. Work from our group (Christensen et al.) and others 
(Gracey Maniar et al.; Riu et al.) has shown that plasmid DNA becomes occupied by 
histones, which may contribute to transgene silencing in human cells. In a previous 
study, we used DNA sequences that were known targets of endogenous activation-
associated proteins to reduce silencing of a luciferase reporter gene (Zimmerman et 
al.). Here, we tested additional motifs (Figure 2.2a) that are recognized by AAPs 
from the transcriptional activator group in our panel: MYB and p65 (Figure 2.1).  
One of three MYB enhancer variants or the p65 enhancer was placed in either 
a forward or reverse orientation upstream of an EF1a promoter and a luciferase 
reporter (Figure 2.2b). PC-3 (human prostate cancer) cells were transfected with 
each plasmid as described previously (Zimmerman et al.). The highest levels of 
enhanced expression were observed for MYB variant A (4.5-fold, p = 0.03) or p65 
(5-fold, p = 0.08) placed in the reverse orientation (Figure 2.2c). Interestingly, 
switching the orientation of these motifs eliminated the enhancement 
effects.  Nonetheless, these results suggest that cis-regulatory elements from the 
p65 and MYB systems can be used to attract endogenous transcriptional activators to 
a synthetic promoter to drive transgene expression.  
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Figure 2.2: Luciferase expression from MYB- and p65-enhancer constructs. A) 
Enhancer motif logos for MYB and p65 were generated by JASPAR (Mathelier et al.). 
The MYB sequence includes a variable site (V) equally occupied by A, C, or G 
nucleotides. B) Luciferase reporter constructs (center) included one of the enhancer 
sequences (MYB-A +, etc.) 19 bp upstream of an EF1α promoter, or no enhancer 
(Control). C) Luciferase assays were carried out using PC-3 cells transfected with 
Lipofectamine-plasmid complexes. For each transfection, luminescence (luc signal) 
values were measured in triplicate and normalized to the average signal from the 
Control. Circle = mean normalized signal from a transfection, error bars = standard 
deviation. Wide bars represent the average of three transfections. Asterisks (*) = p 
< 0.05 for the experimental average, relative to the Control average. 
 
2.2.3 Identification of fusions with robust activity within Polycomb heterochromatin 
 
Next, we asked whether the individual peptides MYB and p65, as well as other 
AAPs could enhance transgene expression in the absence of a specific enhancer 
sequence. To determine AAP activity within silenced chromatin, we targeted AAP 
fusion proteins (Figure 2.1) to a chromosomal luciferase reporter that had been 
previously targeted by Polycomb repressive complexes (PRCs). The AAP open 
reading frames (ORFs) encode catalytic subunits or full length proteins (Figure 2.3) 
that have been shown to support an epigenetically active state in various prior 
studies (Beerli et al.; P. Q. Liu et al.; Zobel et al.; Kawasaki et al.; L. Yang et al.; 
Milne et al.; Nishioka et al.; Antonysamy et al.; Clark et al.; Serandour et al.; W. 
Wang et al.). All of these ORFs exclude DNA binding and histone binding domains, 
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except for the ORF encoding FOXA1 which has a catalytic domain that requires 
histone interactions. We cloned each ORF into mammalian vector 14 (MV14) (Figure 
2.3) to express a Gal4-mCherry-AAP fusion. The Gal4 DNA binding domain serves as 
a module to target AAPs to UAS sequences in the transgene, while the mCherry tag 
allows for protein visualization and quantification of the activator fusion. 
 
 
Figure 2.3: Design and construction of activation-associated peptide (AAP) -Gal4 
fusions. Amino acid lengths are indicated as well as domain location within the full-
length wild-type sequence (Appendix A, Table 2A). ORFs were cloned into MV14 to 
express a Gal4-AAP fusion protein from a cytomegalovirus (CMV) promoter. Gal4-
AAPs are expressed with a C-terminal nuclear localization signal (NLS) and a 6X 
histidine tag. MV14 expresses puromycin resistance to enable selection of Gal4-AAP 
positive cells. 
 
 
We tested all sixteen Gal4-AAP candidate fusion activators at repressive 
chromatin in HEK293 (human embryonic kidney) cells. The HEK293 cell line Gal4-
EED/luc, carries a stably integrated firefly luciferase transgene with an upstream 
Gal4UAS (Gal4UAS-Tk-luciferase) (Figure 2.4a) (Hansen et al.; Daer et al.).  The 
cells also carry a TetO-CMV-Gal4EED construct, which encodes a Gal4 DNA-binding 
domain (Gal4) fused to an embryonic ectoderm development (EED) open reading 
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frame under the control of TetO-CMV promoter (Figure 2.4a). Expression of the Gal4-
EED fusion protein is controlled by a Tetracycline repressor (TetR). The addition of 
doxycycline (dox) to cultured Gal4-EED/luc cells releases the TetR protein from TetO-
CMV-Gal4EED, initiating expression of Gal4-EED. Gal4-EED binds to the Gal4UAS site 
upstream of luciferase, recruiting PRC2 to the reporter. Expression of luciferase is 
switched from active to silenced through accumulation of Polycomb chromatin 
features, which have been detected by chromatin immunoprecipitation (ChIP) 
experiments: EZH2, Suz12, CBX8, depletion of H3K4me (Hansen et al.), and gain of 
H3K27me3 (Hansen et al.; Daer et al.). This system allows us to test the activity of 
Gal4-AAPs with a priori knowledge of the chromatin environment at the target gene. 
 Gal4-EED/luc cells were treated with dox for 48 hours to induce Polycomb 
heterochromatin at the luciferase transgene. Afterwards, dox was removed and cells 
were grown for four days without dox to allow for Gal4-EED depletion. Cells were 
then transfected with individual Gal4-AAP plasmids. Luciferase expression was 
measured 72 hours post transfection.  
Three of the sixteen Gal4-AAP-expressing samples showed increased 
luciferase levels compared to a mock-transfected control (Lipofectamine reagent 
only) (p < 0.05) (Figure 2.4a). Lack of enhanced luciferase expression for the other 
fusions could have been due to strong inhibition by PRC complexes or failure of the 
AAPs to function as Gal4 fusions at the UAS site. Therefore, we also tested the 
activities of the fusion proteins within open chromatin. We used a parental HEK293 
cell line, Luc14, that carries the firefly luciferase construct (Gal4UAS-Tk-luciferase) 
but lacks the TetO-CMV-Gal4EED repression cassette (Figure 2.4b) (Hansen et al.). 
Luciferase is constitutively expressed at high levels in Luc14.  
 We found a similar trend of expression enhancement at open chromatin in 
Gal4-AAP-expressing cells (Figure 2.4b), where only three Gal4-AAP fusions were 
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able to stimulate expression when positioned at the promoter-proximal UAS (Figure 
2.4b). In both chromatin states, AAPs from the transcriptional activation group 
(Figure 2.1, Figure 2.3) significantly increased expression compared to a mock 
transfection control (p < 0.05) by up to five fold. Our results are consistent with 
previous studies where p65, VP64, or MYB stimulated gene expression from a 
promoter-proximal site (P. Q. Liu et al.; Beerli et al.; Weston and Michael Bishop). 
Here, we have demonstrated activities of these proteins within highly PRC-enriched 
chromatin. 
 
Figure 2.4: Measurement of luciferase reporter expression within closed or open 
chromatin after exposure to Gal4-AAP fusions. A) In Gal4-EED/luc HEK293 cells, PRC 
is recruited to the Tk-luciferase reporter gene via Gal4-EED (induced by dox). 
Treated cells were transfected with each Gal4-AAP fusion plasmid. Seventy-two 
hours post transfection luciferase signal was measured. Each circle in the bar graph 
shows the mean luciferase (Luc) signal for a single transfection, divided by cell 
density (total DNA, Hoechst staining signal). Bars show means of three transfections. 
Asterisks (*) = p < 0.05 compared to untransfected cells.  B) The same procedure 
was carried out for unsilenced Tk-luciferase (in Luc 14 cells). 
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2.2.4 Fusion-induced activation is sustained after loss of the Gal4-AAP transactivator 
 
The results so far were obtained at a single time point after Gal4-AAP 
expression. We were interested in determining whether transgene activation within 
Polycomb chromatin is stable or is transient and susceptible to eventual re-silencing 
(Pirrotta). To investigate this question, we performed time-course experiments to 
measure expression from re-activated luciferase over time. We induced Polycomb 
heterochromatin in Gal4-EED/luc cells as described for the previous experiments. 
Twenty-four hours post transfection with one of the strong activators, Gal4-p65, -
VP64, or -MYB, cells were grown in medium supplemented with 10 µg/mL puromycin 
to select for Gal4-AAP positive cells. Seventy-two hours post transfection, we 
measured luciferase expression, Gal4-AAP mRNA levels, and mCherry fluorescence 
from a sample of each transfected culture. The cells were then passaged in 
puromycin-free medium to allow for loss of Gal4-AAP, sampled every four days 
(approximately three generations), and the same three measurements (luciferase, 
Gal4-AAP mRNA, and mCherry) were repeated at each time point.  
 We found that transient induction by Gal4-AAPs was sufficient to induce 
mitotically heritable reactivation of Tk-luciferase in Polycomb heterochromatin. For 
all three Gal4-AAP fusions, luciferase expression was significantly increased at most 
time points and at 456 hours (p < 0.05) compared to a mock transfection control 
(Lipofectamine reagent only) (Figure 2.5a). In two of the three additional trails, 
Gal4-p65 and Gal4-MYB showed at least ~2-fold enhancement at 360 hours 
(Appendix A, Figure A1). Steep declines of Gal4-AAP mRNA and mCherry 
fluorescence after 72 hours (Figures 2.5b, 2.5c) confirmed the transient presence of 
the transactivators. Therefore, enhancement of luciferase expression persisted long 
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after depletion of each Gal4-AAP, suggesting heritable epigenetic memory of the 
activated state.  
 
Figure 2.5: Expression of Polycomb-repressed Tk-luciferase over time after 
expression and loss of Gal4-p65, Gal4-VP64 or Gal4-MYB. A) Gal4-EED/luc cells were 
treated with dox to induce Polycomb chromatin, transfected with a Gal4-AAP 
plasmid, and grown under puromycin selection (10 µg/mL). At 72 hours post 
transfection, cells were sampled for luciferase (Luc) assays, passaged in puromycin-
free medium, then sampled 168, 264, 360, and 465 hours post transfection for 
additional Luc assays. Mean Luc signal per cell is presented as described for Figure 4, 
except individual values (circles) at each time point are normalized by the mean of 
the "No activator" negative control. Asterisks (*) = p < 0.05 compared to the 
negative control. Results from replicate trials are shown in Appendix A, Figure A1. B) 
Reverse transcription followed by quantitative PCR (RT-qPCR) with primers against 
mCherry was used to determine Gal4-AAP transcript levels. “mRNA fold change” 
represents the Cq value normalized by the Cq of a housekeeping gene (TBP), and 
relative to mock-transfected “No activator” cells (Lipofectamine reagent only), log2 
transformed. C) Flow cytometry of mCherry signal (red fluorescent protein, RFP) was 
used to determine Gal4-AAP protein levels. Data in B and C were generated from one 
set of transfections in A. For other samples, cells were visually inspected for RFP to 
verify the loss of Gal4-AAP. 
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2.2.5 MYB-mediated activation within closed chromatin requires interactions with a 
histone acetyltransferase 
 
Next, we used specific chemical inhibitors to probe the mechanism of MYB-
driven enhancement. The TAD core acidic domain of human MYB (D286-L309) 
included in our Gal4-MYB fusion construct is known to interact with a protein 
heterodimer of p300 and CBP (Appendix A, Figure 2A). A single base pair mutation 
within the MYB TAD domain (M303V) disrupts p300 recruitment and subsequent 
activation by MYB indicating that this recruitment is crucial to activation by MYB 
(Sandberg et al.; Pattabiraman et al.). The p300/CBP histone acetylation complex 
deposits H3K27ac in opposition to H3K27me3 induced by PRC2 (Raisner et al.; 
Ogryzko et al.). Therefore, induced activation within Polycomb heterochromatin may 
be driven by histone acetylation. 
To test this idea, we treated cells with two compounds that are known to 
disrupt the activity of the MYB/p300/CBP complex. Celastrol is a minimally toxic 
pentacyclic triterpenoid that directly inhibits the MYB/p300 interaction, by binding to 
the KIX-domain of CBP which serves as a docking site for the formation of the 
MYB/p300/CBP complex (Coulibaly et al.; Uttarkar, Piontek, et al.; Denis et al.; 
Uttarkar, Dassé, et al.) (Figure 2.6a). C646, a pyrazolone-containing small molecule, 
binds the p300 catalytic domain and thus directly and selectively inhibits p300 HAT 
activity regardless of its association with MYB (Figure 2.6a) (Y.-M. Wang et al.; Oike 
et al.; Bowers et al.). These compounds allow us to resolve the roles of complex 
assembly and p300-mediated histone acetylation during Gal4-MYB-mediated 
activation. 
Gal4-EED/luc cells were treated with dox to induce Polycomb chromatin and 
transfected with Gal4-MYB as described for previous experiments. We treated these 
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cells with 5 µM celastrol or 5 µM C646 for six hours. MTT assays indicated no toxicity 
to HEK293 cells at this concentration (Appendix A, Figure A3). We expected 
luciferase assays to show a decrease in Gal4-MYB-induced expression in drug-treated 
cells compared to an untreated control. We observed a significant (p < 0.05) 
decrease in luciferase expression in celastrol-treated cells, but not in C646-treated 
cells (Figure 2.6b). This result suggests that Gal4-MYB activity requires MYB TAD and 
p300/CBP assembly, while p300 HAT activity is dispensable. The other two strong 
activators, Gal4-VP64 and -p65, were insensitive to celastrol and C646 (Figure 2.6b), 
indicating a p300/CBP-independent mechanism for these two fusions.  
In a time-course experiment using celastrol, we observed that Gal4-MYB-mediated 
activation is reversible. Eighteen hours after removal of celastrol from Gal4-MYB-
treated cells, luciferase expression levels increased (p < 0.05 compared to 
repression at t = 6), nearly restoring expression to original levels (t = 0) (Figure 
2.6c). Re-addition of celastrol led to a loss of Gal4-MYB induced expression (Figure 
2.6c).  
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Figure 2.6: Celastrol disrupts Gal4-MYB-mediated activation of luciferase in closed 
chromatin. A) The p300/CBP complex acetylates histones via the catalytic HAT 
domain of p300 and/or CBP (Ogryzko et al.). Celastrol inhibits the recruitment of 
p300/CBP by MYB by binding a docking domain in CBP that facilities complex 
assembly (Uttarkar, Dassé, et al.; Uttarkar, Piontek, et al.). C646 disrupts histone 
acetylation by binding the active site of p300 (Bowers et al.). B) Seventy-two hours 
after Gal4-EED-mediated repression of Tk-luciferase and transfection with Gal4-
AAPs, cells were treated with either 5 µM celastrol or 5 µM C646 for six hours and 
collected for luciferase assays. Mean luciferase (Luc) signal per cell is presented as 
described for Figure 4. Asterisks (*) = p < 0.05 compared to Gal4-MYB without drug 
treatment.  C) Luc measurements were carried out in Gal4-MYB-expressing cells 
after removal (-) and re-addition (+) of celastrol. Each series represents an 
independent transfection. Point = mean of three luciferase assays, bars = standard 
error. 
 
 
2.2.6 MYB-mediated activation in Polycomb heterochromatin relies upon proximity to 
the transcriptional start site 
 
Next we asked whether MYB-mediated activation at transgenes is context 
dependent. We leveraged the flexible dCas9/sgRNA system to target the MYB TAD to 
several sites along the luciferase transgene (Figure 2.7a). To do so, we targeted 
sites at different positions within the Tk-luciferase gene. We also tested the MYB TAD 
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at a different transgene, CMV-GFP in HEK293, that had become silenced after several 
passages (C. Liu, unpublished). 
 We induced Polycomb heterochromatin in HEK 293 Gal4EED/luc cells with 
dox, followed by washout of dox to allow Gal4-EED depletion as described above. We 
transfected the cells with one of four dCas9-MYB constructs, each carrying a different 
sgRNA targeted at the luciferase transgene. After 72 hours, we tested luciferase 
expression and found that dCas9-MYB targeted nearest the transcription start site 
(+9) was able to restore levels of expression similarly to Gal4-MYB (Figure 2.7b). In 
induced Polycomb heterochromatin we observed clear position effects, as the 
downstream target sites show levels of activation significantly lower than Gal4-MYB 
(p < 0.05). 
 After determining the viability of dCas9-MYB to act as an activator for silenced 
transgenes in a defined chromatin environment, we wanted to test this domain 
against endogenous heterochromatin at the CMV-GFP transgene. The construct, GFP 
under the control of a CMV promoter, was inserted via Cas9-mediated HDR into a 
non-protein-coding region of the HEK293 genome (HEK293 site 3 (Tsai et al.)). We 
transiently transfected the cells with dCas9-MYB constructs, each carrying one of 
four different sgRNAs targeted upstream, within the promoter, or in the coding 
region of the transgene. Seventy-two hours post transfection, we used flow 
cytometry to measure GFP fluorescence compared to a mock-transfected control 
(Lipofectamine reagent only). We found that GFP fluorescence was significantly 
higher (p < 0.05) in all dCas9-MYB-expressing cells regardless of sgRNA position 
(Figure 2.7c), indicating that MYB-mediated activation does not require proximity to 
the TSS in all contexts. 
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Figure 2.7: dCas9-MYB’s ability to enhance expression in induced Polycomb 
heterochromatin is dependent upon distance from the promoter. A) Expression 
vector pX330g_dCas9-MYB was constructed from vector pX330A_dCas9 (a gift from 
Takashi Yamamoto, Addgene plasmid #63598) to co-express a dCas9-MYB fusion 
protein and mCherry from a CBh promoter. Single-stranded guide RNA sequences 
(Appendix A, Table A3) were cloned into the BbsI sites and expressed from a hU6 
promoter on the same vector. B) We targeted dCas9-MYB to four locations (g46, 
g32, g31, g25) across the Tk-luciferase transgene in silenced Gal4-EED/luc cells. 
Mean luciferase signal per cell is presented as described for Figure 4. The control 
(grey bar) is a mock-transfection with Lipofectamine (No Activator, NA). C) We 
targeted dCas9-MYB to four sites (L1-4) across a chromosomal CMV-GFP transgene 
in HEK293 cells. Seventy-two hours post transfection with dCas9-MYB/sgRNA vectors 
or mock transfection, we measured GFP fluorescence via flow cytometry. Circle = 
median GFP fluorescence value from one transfection, 10,000 cells; bars = means of 
three transfections. In B and C, asterisks (*) = p < 0.05 for experimental mean 
compared to the NA control mean. 
 
2.3 Discussion 
 
We have demonstrated that DNA enhancer elements and fusion proteins 
derived from endogenous mammalian systems can be used to support strong 
expression from transgenes. Furthermore, we have successfully demonstrated long-
term reactivation of a transgene that had been previously silenced by ectopic 
Polycomb heterochromatin. Transient induction of activation by Gal4-AAPs is 
sufficient to maintain an active state over nearly fifteen generations of cell division. 
These results have exciting implications for achieving reliable expression of synthetic 
DNA in engineered cells, as well as our understanding of inherited chromatin states. 
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Our results also suggest that the mechanism of artificial transgene 
reactivation within Polycomb heterochromatin requires assembly of transcription 
initiation complexes. From STRING analysis, we found no clear pattern of histone 
modifications to distinguish the inactive Gal4-AAPs from activators that were able to 
enhance expression in Polycomb heterochromatin (Figure 2.1). We observed that 
several of the fusion proteins did not restore expression from the Polycomb-
repressed luciferase transgene in HEK293 cells (Figure 2.4a). Thus, Gal4-tethered 
proteins might be functional but not sufficient, are non-functional (sterically 
hindered), or require positioning within non-coding DNA such as enhancer elements. 
For instance, a p300 fusion has shown strong activation of MyoD and Oct4 when 
positioned 5-20 kb upstream at an enhancer (Hilton et al.). Future work could be 
done to systematically test the AAPs at endogenous enhancers.  
Upon further investigation we determined that assembly of the MYB TAD with 
P300/CBP is critical for Gal4-MYB-mediated activation within Polycomb chromatin. 
Inhibition of p300 HAT activity via C646 did not disrupt Gal4-MYB function (Figure 
2.6b). Furthermore, the Gal4 fusion that included only the p300 HAT domain failed to 
activate Polycomb-repressed Tk-luciferase (Figure 2.3, Figure 2.4). Therefore the 
p300 catalytic domain alone is neither necessary nor sufficient to reverse epigenetic 
silencing under the conditions tested here. CBP, which is also a histone 
acetyltransferase, might compensate for p300 in C646-treated cells (Ogryzko et al.). 
Celastrol inhibits the interaction of p300/CBP with MYB by binding to the CBP KIX 
domain (Uttarkar, Dassé, et al.; Uttarkar, Piontek, et al.; Coulibaly et al.; Denis et 
al.), and completely reduces Gal4-MYB activity (Figure 2.6b). In contrast to C646, 
celastrol may disrupt the recruitment of both HAT enzymes, p300 and CBP.  
In contrast to Gal4-MYB, the Gal4-p65 and -VP64 fusions showed robust 
activation of PRC-silenced luciferase in the presence of both inhibitors (Figure 2.6b). 
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Although VP64 (VP16) and p65 are known to interact with p300/CBP, they also 
interact with the large multi-subunit Mediator complex to initiate transcription (van 
Essen et al.; Thakore et al.; Wei Wang et al.). Multiple interactions of Gal4-p65 and -
VP64 with Mediator may allow these proteins to function independently of p300/CBP 
(Lecoq et al.). However in the case of Gal4-MYB, cooperative interactions between 
p300/CBP and Mediator (Z.-Q. Huang et al.; Haas et al.) may be necessary for gene 
activation. In our study, Mediator complex recruitment arises as a particularly potent 
mechanism of transgene reactivation in Polycomb heterochromatin (Haas et al.). 
Mediator is known to cooperatively regulate PRC2 repression (Fukasawa et al.) and 
certain Mediator subunits are directly involved in the removal of PRC2 from 
endogenous promoters (Englert et al.). Similarly, Mediator has an antagonistic 
relationship with the PRC1 repression complex (Lehmann et al.). 
The inhibitor experiments also suggest a novel technique for chemically 
inducible gene regulation in mammalian cells. The ability to quickly toggle between 
enhanced and repressed states is a cornerstone technology for the control of 
engineered transgenic systems (Oakes et al.; Kramer et al.; Greber et al.). Current 
methods for toggling gene expression in mammalian cells employ drug-mediated 
transactivator localization, such as allosteric modulation of DNA-binding protein 
domains (Stanton et al.; Kramer et al.; Oakes et al.), blue light-responsive CRY 
proteins (Mansouri et al.), and chemically induced dimerization (CID) systems (Inobe 
and Nukina; Rivera et al.; DeRose et al.), or RNA interference to deplete the 
regulator (Greber et al.). To our knowledge, no systems currently exist where the 
transactivation module’s activity (i.e., MYB-CBP binding) is modulated by a small 
molecule drug. Celastrol has a low toxicity and is in fact being explored as a 
therapeutic due to its positive effects on the immune system (Cascão et al.; 
Venkatesha et al.; Ju et al.). The concentration of celastrol that is sufficient to toggle 
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Gal4-MYB activity in Polycomb chromatin is well below any reported LD50 values for 
celastrol (Li et al.; Raja et al.; H. Yang et al.; Cleren et al.; Konieczny et al.). 
Finally, our work demonstrates the potential flexibility of MYB fusion proteins as 
transactivators. dCas9-MYB showed strong activation of previously silenced 
transgenes near two different promoter elements, Tk and CMV. Tk had undergone 
silencing by ectopic Polycomb chromatin, whereas CMV had become silenced by 
undetermined mechanisms. Interestingly, stimulation of expression from PRC-
repressed Tk seemed to require TSS-proximal positioning of Gal4-MYB, whereas 
Gal4-MYB stimulated expression from both upstream (up to 1400 bp) and 
downstream (up to 350 bp) of the CMV TSS. Factors that might account for this 
difference include intrinsic differences in the core promoter sequences, the presence 
of cryptic enhancers at one promoter and not the other, and differences in chromatin 
structure. To our knowledge, our work represents the first use of MYB as a dCas9 
fusion that can activate a transgene from proximal and distal locations. 
 
2.4 Conclusion 
 
In conclusion, we have determined a predominant role for p300/CBP-recruiting 
transcriptional activators in the reversal of Polycomb-mediated expression in the 
context of synthetic transgene regulation. In particular, we have expanded the 
characterization of the transcriptional activator protein MYB and its associated 
enhancer DNA sequence for applications in artificial gene regulation in mammalian 
cells. 
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2.5 Methods 
 
2.5.1 Construction and Testing of Plasmids Containing MYB- and p65 Motifs 
 
Plasmid construction, transfection of PC-3 cells, and luciferase assays were 
carried out as described previously (Zimmerman et al.).  Briefly, cloning of double-
stranded oligos was used to insert motifs 222 bp upstream of the transcription start 
site of an EF1a promoter at XbaI/SpeI.  Plasmids were then transfected into PC-3 
cells (ATCC, CRL-1435) using Lipofectamine LTX™ following the manufacturer’s 
recommended protocols. Luciferase expression was measured 48 hours after 
transfection using a luciferase assay kit (Promega, Madison, WI). All luciferase values 
were normalized relative to the native plasmid control, which contained an unaltered 
EF1a promoter. 
 
2.5.2 Construction of MV14 and Gal4-AAP Plasmids 
 
We constructed mammalian expression vector 14 (MV14) for the 
overexpression of Gal4-mCherry-AAP fusion proteins in-frame with a nuclear 
localization sequence and 6X-histidine tag. First, plasmid MV13 was built by inserting 
a Gal4-mCherry fragment into MV10 (Tekel et al.) directly downstream of the CMV 
promoter. Next, MV14 was built by inserting a SpeI/PstlI (FastDigest enzymes, 
ThermoFisher Scientific) -digested gBlock Gene Fragment (Integrated DNA 
Technologies), which encoded a XbaI/NotI multiple cloning site, into MV13 
downstream of mCherry. Ligation reactions included gel-purified (Sigma NA1111) 
DNA (25 ng linearized vector, a 2x molar ratio of insert fragments), 1x Roche RaPID 
ligation buffer, 1.0 µL T4 ligase (New England Biolabs), in a final volume of 10uL. 
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 AAPs were cloned into MV14 at the multiple cloning site containing XbaI and 
NotI cut sites. AAPs were either ordered from DNASU in vectors and amplified using 
primers that added a 5’ XbaI site and a 3’ NotI site or ordered as gBlock Gene 
Fragments with the same 5’ and 3’ cutsites (Integrated DNA Technologies). 
Sequences in vectors were amplified with Phusion High Fidelity DNA Polymerase 
(New England BioLabs) and primers listed in Appendix A, Table A2. MV14 and AAP 
inserts were double-digested with FastDigest XbaI and FastDigest NotI 
(ThermoFisher Scientific) and then ligated with T4 DNA ligase (New England Biolabs). 
MV14_AAP plasmids are publically available through DNASU (Appendix A, Table A4) 
 
2.5.3 Cell Culturing and Transfections 
 
Luc14 and Gal4-EED/luc HEK293 cells were grown in Gibco DMEM high 
glucose 1× (Life Technologies) with 10% Tet-free Fetal Bovine Serum (FBS) (Omega 
Scientific), 1% penicillin streptomycin (ATCC) at 37 °C in a humidified 5% CO2 
incubator. Gal4-EED/luc cells were treated with 1 µg/mL doxycycline (Santa Cruz 
Biotechnology) for 2 days to induce stable Polycomb repression. Dox was removed 
and cells were cultured for another four days before being seeded in 12-well plates. 
Luc14 cells and dox-induced Gal4-EED/luc cells were seeded in 12-well plates such 
that cells reached 90% confluency for lipid-mediated transfection. Transfections were 
performed with 1 µg plasmid per well, 3 µL Lipofectamine LTX, and 1 µL Plus 
Reagent (Life Technologies) per the manufacturer’s protocol. Seventy-two hours post 
transfection, cells were either collected for analysis or passaged further. 
 Puromycin selection was carried out on Gal4-AAP-expressing cells for the 
experiments represented in Figure 5 and Figure A1. Dox-treated Gal4-EED/luc cells 
were transfected in 12-well plates and then grown for 24 hours before the addition of 
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10 µg/mL puromycin (Santa Cruz Biotechnology) to Gibco DMEM high glucose 1× 
(Life Technologies) with 10% Tet-free Fetal Bovine Serum (FBS) (Omega Scientific), 
1% penicillin streptomycin (ATCC). Cells were grown in puromycin containing media 
for two days before wash out. 
 
2.5.4 Luciferase Assays 
 
Luciferase assays were performed as previously described in Tekel et al. 
(Tekel et al.). In brief, a single well of cells from a 12 well tissue culture plate was 
collected per independent transfection in 1.5mL 1X PBS. Cells were loaded into 9 
wells of a Black Costar Clear Bottom 96 Well Plates (Corning #3631). Three wells of 
cells were used to detect mCherry in order to quantify Gal4-AAP proteins. A 2X 
Hoechst 33342 stain (Invitrogen #H3570) was loaded into three more wells to stain 
nuclear DNA in order to quantify cell density. The final three wells were prepared 
with Luciferase Assay Buffer (Biotium #30085). Plates were scanned in a microplate 
reader (Biotek Synergy H1) to detect RFP (580 nm - 610 nm), Hoechst 33342 
fluorescence (360 nm - 460 nm) and chemiluminescence from the same sample in 
parallel. 
 
2.5.5 RT-qPCR 
 
We prepared total RNA from ~1.0 x 106 cells (Qiagen RNeasy Mini kit 74104) 
and generated cDNA from 2 µg of total RNA and the SuperScript III First Strand 
Synthesis system (Invitrogen #18080051) in a reaction volume of 20 µL. 
Quantitative PCR (qPCR) was performed with universal primers against the mCherry 
portion of the Gal4-AAP fusions, or the TATA binding protein (TBP) housekeeping 
gene. Triplicate qPCR reactions (10 µL) each contained SYBR Green 1 2X master mix 
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(Roche), 2 µl of a 1:10 cDNA dilution, and 750 nM of each primer (forward and 
reverse, see Table A5). We calculated Mean Quantification Cycle (Cq) for three 
replicate wells per unique reaction. Change in gene expression level was calculated 
as  ΔCq = 2[Mean Cp reference − Mean Cp target]. Log2 fold change in gene expression was 
calculated as = log2(ΔCq transfected cells / ΔCq mock). 
 
2.5.6 Flow Cytometry 
 
Cells were passed through a 35 µm nylon strainer (EMS #64750-25). Green 
fluorescent signal from GFP and red fluorescent signal from mCherry were detected 
on a BD Accuri C6 flow cytometer (675 nm LP filter) using CFlow Plus software. Data 
were further analyzed using FlowJo 10.5.3. One run (∼10 000 live cells, gated by 
forward and side scatter) was completed per sample, allowing us to determine 
median fluorescence within the live cell population.  
 
2.5.7 Construction of dCas9-MYB and Design of sgRNAs 
 
We modified the vector pX330A_dCas9–1 × 4 (a gift from Takashi Yamamoto, 
Addgene plasmid #63598) by inserting a gBlock Gene Fragment (Integrated DNA 
Technologies) encoding the MYB TAD followed by a p2A signal (Z. Liu et al.) and 
mCherry after the dCas9 ORF. The resulting vector expresses a dCas9-MYB fusion 
and mCherry as separate peptides from a single mRNA transcript. The vector and 
gBlock were digested with FseI (New England BioLabs) and FastDigest EcoRI 
(ThermoFisher Scientific) and ligated using T4 DNA Ligase (New England BioLabs). 
We named this new vector pX330g_dCas9-MYB. SgRNAs used in the study (Appendix 
A, Table A3) were designed using the CRISPR design tool at crispr.mit.edu. DNA 
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oligos were synthesized with BbsI overhangs for cloning into pX330g_dCas9-MYB 
(Integrative DNA Technology). Drop-in of sgRNAs followed the cloning protocol 
described in Cong et al. (Cong et al.). 
 
2.5.8 Celastrol and C646 Treatments 
 
Gal4-EED/luc cells were induced with dox and transfected as described above. 
Three days post transfection, cells were treated with either C646 (Selleck Chemicals) 
or Celastrol (Selleck Chemicals) diluted to a concentration of 5µM in Gibco DMEM 
high glucose 1× (Life Technologies) with 10% Tet-free Fetal Bovine Serum (FBS) 
(Omega Scientific). Cells were incubated with the drug for six hours before being 
washed and either harvested for a luciferase assay or grown further in drug-free 
media.  
 
2.5.9 Statistical Analyses 
 
The differences of means were calculated using the two sample, one-tailed 
Student’s t test. For p < 0.05, confidence was 95% for 2 degrees of freedom and a 
test statistic of t(0.05,2) = 2.920. To evaluate significance of Gal4-MYB induced activation 
after the removal of celastrol and its subsequent re-addition, a nest one-way ANOVA 
was used with 95% confidence and two degrees of freedom. 
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CHAPTER 3 
METHODS FOR VISUALIZING FUSION PROTEIN TOOLS IN MAMMALIAN CELLS 
 
3.1 Background 
 
Visualizing proteins is essential to our ability to engineer their functionality. 
Visualization of native proteins allows us to gain new information about their 
localization, expression, and longevity within the cell (Chudakov et al.; Rizzo et al.; 
Allen and Budowle). When working with engineered proteins expressed from 
transgenic material within the cell, visualization facilitates troubleshooting of those 
same parameters. Localization, expression, and longevity of proteins are all tunable 
elements in the design phase that we adjust to suit a certain need (Pleiss). This 
makes tracking them in the test phase especially crucial to determine if iteration of 
the design-build-test cycle is required. Visualization of proteins is a key testing-
phase tool that facilitates this. 
 Historically, the use of isotope or colorimetric markers such as protein specific 
dyes has been used to quantify protein expression and location to particular 
organelles (Becker; Alturkistani et al.). While these approaches are still commonly 
used in histology, they lack the resolution required to provide quantitative data (low 
sensitivity) and often permeate the cell inducing mortality (destructive). This 
prohibits the tracking of protein expression and localization within the same cell over 
time. More advanced approaches typically involve the use of fluorescent labeling, 
which has the advantage of being usable in live cells (non-destructive) and showing 
protein localization to a high resolution (high sensitivity) (Rizzo et al.). This also 
mitigates safety concerns around the use of radiation and certain carcinogenic dyes.  
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 Direct visualization also has some key advantages over the use of nucleic acid 
detection methods for expression tracking. While quantitative PCRs are an invaluable 
tool for tracking expression over time, they are necessarily destructive and lack the 
high-throughput capacity of methods such as flow cytometry. Fluorescent tags also 
provide spatial information that PCR methods cannot.  
 Transgenic systems can be visualized through fluorescence at various stages 
of expression. Here we investigate three facile approaches that can be used to 
visualize transgenic expression of targeted epigenetic effectors (Figure 3.1), 
comprised of a Gal4 DNA binding domain and activation-associated peptide (Gal4-
AAPs). These fusion proteins were designed to open closed chromatin, a function 
that pioneer factors perform in native systems. In Chapter 2, we explored the ability 
of these fusion proteins to increase expression. We needed to use fluorescent 
labeling to quantify their expression so as to normalize the strength of their 
epigenetic effects by protein quantity. In Chapter 4, we discuss their ability to not 
only activate gene expression, but to develop a more accessible chromatin 
environment. With this dual functionality, we have decided to term these fusion 
proteins Synthetic Pioneer Factors (SPiFs). Visualization of SPiFs is crucial to the 
cell-sorting methodology used in Chapter 4 as well. This chapter details the 
fluorescent labeling approaches tested to visualize SPiFs 1) in live cells, 2) in parallel 
to assaying their epigenetic functionality, and 3) in high-throughput. All of these 
parameters are critical to our full investigation of SPiF functionality. For a full panel 
of the SPiFs used in these tests, see Chapter 2. 
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Figure 3.1: Detectable fluorescent elements used in fusion protein detection have 
unique pros and cons. Direct detection of a fluorescent protein fused to other 
construct elements is both facile and low cost, however, variations in folding 
dynamics may disrupt reliable detect in single cells. The use of tag-specific 
antibodies is costly but has a high degree of sensitivity (National Research Council et 
al.; Frerichs). Finally, the detection of fusion protein expression at the RNA level via 
the use of a fluorescent aptamer is low cost, both financially and metabolically, but 
does not provide spatial protein information. 
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The initial design of the SPiFs included an mCherry protein between the Gal4 
DNA binding domain and terminal activation-associated peptide (Figure 3.1). This 
inclusion of a fluorescent protein within the fusion protein itself is an extremely 
common labeling practice in synthetic biology (Hoffman). The use of green 
fluorescent protein (GFP) as a fluorescent reporter and tag was the subject of the 
2008 Nobel Prize in Chemistry (Shimomura). Since that time a rainbow of derivatives 
has been developed, allowing researchers to use multiple tags in parallel that do not 
have overlapping emission spectra (Shimomura; Follenius-Wund et al.). GFP-family 
proteins are typically comprised of a beta-barrel structure with an internal 
chromophore, making folding dynamics crucial to fluorescent functionality of the 
protein (Figure 3.1) (Orm et al.).  
 An external approach to fluorescent labeling is the use of fluorescently labeled 
antibodies targeted at tagged fusion proteins (Figure 3.1) (Griffiths). This approach 
allows the target of labeling to be easily changed without full reconstruction of your 
fusion protein. The labeling process is also highly specific but comes at both a high 
financial price and a cost to cell viability as permeabilization is necessary for antibody 
staining. However, this approach does allow for labeling regardless of most changes 
in fusion protein folding dynamics. 
 The final approach we investigated was the inclusion of a fluorescent RNA 
aptamer within the SPiF transcript itself (Figure 3.1) (Filonov et al.; Okuda et al.). 
This alternative to direct protein visualization still provides a proxy measurement for 
expression in vivo as well as duration of expression. RNA aptamers are also 
metabolically cheap and do not interfere with folding dynamics and fusion protein 
functionality. We explored this approach as an additional fluorescent monitor of 
fusion protein expression.  
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In this chapter, we compare three major visual methods to detect fusion 
protein expression by fluorescence, specifically in our SPiF system. Fluorescence 
detection serves as an important control parameter and should be detected in high-
throughput, ideally in parallel to the effects of the fusion protein. 
 
 
3.2 Results 
 
We compared three major methods for fluorescent detection of fusion protein 
detection in vivo. Original construct design and structure for each SPiF can bee seen 
in Chapter 2.  
 
3.2.1 Direct fusion of a fluorescent mCherry tag shows variability across constructs 
 
 Our initial approach was to use direct fusion of a fluorescent beta-barrel 
protein, mCherry, to our epigenetically functional protein domains. This approach 
requires no dyes, staining, or fixation and can be used in high-throughput via flow 
cytometry. The design incorporated an mCherry protein between an N-terminal Gal4 
DNA binding domain and a downstream activation domain (Figure 3.2a). We first 
tested this design for visualization with the commonly used p65 activation domain. 
HEK293 cells were transfected and red fluorescence was visualized by flow cytometry 
(Figure 3.2b) and fluorescent microscopy (Figure 3.2c) at twenty-four and seventy-
two hours post transfection, in order to optimize the time range for protein 
detection. With both methods we observed a detectable change in red fluorescence 
after seventy-two hours (Figure 3.2). 
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Figure 3.2: Visual detection of Gal4_mCherry_p65 fusion proteins. A) HEK293 cells 
were transfected with a plasmid expressing Gal4_mCherry_p65 (see Chapter 2 for 
plasmid map). Fusion proteins were detected via B) flow cytometry (each sample 
represented 10,000 lives cells) and C) fluorescent microscopy at 24 and 72 hours 
post transfection. mCherry expression was not evident until 72 hours post 
transfection via both methods.  
 
Next, we tested a larger panel of our SPiFs to evaluate the ability of mCherry 
signal to be used as a proxy for expression seventy-two hours post transfection. 
Having a robust expression metric would allow us to normalize changes in luciferase 
expression induced by each SPiF in our HEK293 model system (see Chapter 2) to 
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relative loads of SPiF proteins within the cell. To this end, we ran luciferase assays 
(Figure 3.3a) in parallel with flow cytometry (Figure3.3b) to detect mCherry 
expression from each sample. Using this single-cell method, we did not observe 
correlations in activation strength with mCherry signal. Likewise, before harvesting 
we visualized mCherry expression via fluorescent microscopy (Figure 3.3c) and 
noticed high levels of variability across constructs, and across trials (data not 
shown).  
 
 
Figure 3.3: Fluorescent tag signal from SPiFs is inconsistent across SPiF function. 
Silenced Gal4-EED/luc HEK293 cells were transfected with individual SPiF plasmids. 
Seventy-two hours post transfection, A) luciferase expression was measured to 
determine the strength of SPiF activity at the reporter. B) mCherry expression was 
measured in parallel via flow cytometry. Each sample represented 10,000 lives cells. 
C) For each sample, mCherry expression was visually assayed via fluorescent 
microscopy. Error bars represent the standard deviation of three biological replicates.  
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3.2.2 Immunocytochemistry (ICC) yields low SPiF detection in live cells 
 
 After finding construct-dependent variability from our mCherry tags, we 
decided to explore a method of visual detection that does not rely on protein folding 
dynamics. Antibodies allow for highly specific tagging and detection of proteins. Each 
of our SPiFs is constructed with a terminal 6XHis tag. We used a fluorescently 
conjugated AlexaFluor 488 antibody specific to the 6XHis tag to visualize our SPiFs 
via flow cytometry seventy-two hours post transfection (Figure 3.4). Detection rates 
were extremely low using this method, most likely due to significant cell loss during 
antibody staining in a population with relatively low transfection rates (~20%). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: 6XHis tag specific AlexaFluor 488 antibodies do not provide sufficient 
signal of Gal4_p65 in HEK293 cells. Transfected and antibody-stained cells (yellow) 
only show slightly more GFP signal (from the 488 AlexaFluor) as compared to 
transfected cells without antibodies (blue) or mock transfected antibody-stained cells 
(red). Each sample represented 10,000 lives cells.  
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3.2.3 Broccoli aptamers are nearly undetectable from low copy number SPiF plasmid 
 
 RNA aptamers have a lower metabolic burden and reliable folding dynamics 
when positioned at the end of a construct (Di Palma et al.; Filonov et al.). We cloned 
in a 2xd-Broccoli aptamer at the C-terminus of our Gal4_p65 SPiF to see if detecting 
expression at the RNA level would be a more effective than the protein level where 
the large structure of the fusion protein may disrupt beta barrel formation. We 
transfected HEK293 cells with a Broccoli-modified Gal4_p65 construct as well as the 
original broccoli containing plasmid, PAVU6+27-F30-2xdBroccoli (Figure 3.5) (Filonov 
et al.). We then stained cells seventy-two hours post transfection for varying 
durations with two concentrations of DFHBI-1T dye to excite emission (Figure 3.5). 
We detected fluorescence with flow cytometry (Figure 3.5a) and visually through 
fluorescent microscopy (Figure 3.5b). In both cases, we found little to no detectable 
fluorescent signal as compared to the original plasmid.  
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Figure 3.5: 2xd-Broccoli does not provide adequate signal for detection of low copy 
number SPiF plasmids via flow cytometry or fluorescent microscopy. We stained 
HEK293 cells transfected with either Broccoli-modified Gal4_p65 or PAVU6+27-F30-
2xdBroccoli at two different concentrations of DHFBI-1T. A) We were not able to 
detect significant signal from SPiF containing cells, as opposed to a significant 
increase in fluorescence from PAVU6+27-F30-2xdBroccoli transfected cells as 
compared to a mock transfection control. B) We also stained cells for 15 and 30 
minutes at two different concentrations of DFHBI-1T, but were unable to detect 2xd-
Broccoli in Gal4_p65 transfected cells. Cells transfected with the original 2xd-Broccoli 
construct showed abundant signal at both concentrations.  
 
 
 
  86 
3.2.4 Development of a high throughput, parallel detection assay for fluorescence 
and bioluminescence 
 
Several projects in our lab require the parallel detection of a fusion protein’s 
expression levels (as a normalizing factor) and their biological functionality, typically 
assayed by evaluating changes in expression at a luciferase reporter. In several 
cases, we found that low transfection rates and variable folding dynamics called for a 
reliable method to pool detection allowing us to surpass the minimum detection 
threshold of our BD Accuri C6 flow cytometer. To this end, we developed a plate-
reader based method to effectively detect mCherry in both our SPiF constructs and 
other targeted epigenetic modifiers used in our lab (Tekel, Barrett, et al.). These 
include PcTF and its derivatives (Olney et al.; Tekel, Vargas, et al.) that our lab has 
previously tested within induced Polycomb heterochromatin (Figure 3.6a). By using a 
pooled cell method, we were able to yield detectable levels of mCherry in parallel 
with a luciferase assay on the same sample (Figure 3.6) (Tekel, Barrett, et al.). 
Hoechst nuclei staining was used as a proxy for cell count. We also determined plate 
reader detection limits (Appendix B) to ensure that the dynamic range of our 
measurements was fully detectable.  
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Figure 3.6: Microwell plate reader assay to determine fusion protein expression and 
regulation of a target reporter gene. (A) Gal4-EED/luc cells were treated with dox to 
induce ectopic recruitment of Polycomb repressive complex 1 (PRC1), and 
accumulation of H3K27me3 and PRC2 at a luciferase reporter. (B) After luciferase 
silencing, cells were transfected with each fusion-expressing plasmid (see Tekel et al. 
2018), harvested, and aliquoted into a 96-well plate. In this procedure, RFP is used 
to determine fusion protein expression, signal from Hoechst 33342 DNA stain is a 
proxy for cell loading, and luciferase activity indicates gene expression induced by 
each Pc-activator fusion (Tekel, Barrett, et al.). (C) Bar charts show mean 
background-subtracted values from triplicate wells, normalized and scaled as 
described in Methods. Error bars, standard deviation; UT, untransfected cells. (This 
figure and its legend are reprinted here with permission from ACS Publications, 
Copyright © 2018 American Chemical Society Publications) 
 
3.3 Discussion 
 
In this chapter we investigated best practices for the parallel testing of 
epigenetically active fusion protein expression and function. We found that fusion 
proteins containing a medial beta-barrel protein suffered from inconsistent levels of 
fluorescence across construct types, potentially due to diverse protein folding 
dynamics. The C-terminal activation domains fused to the medial mCherry protein 
ranged in length from 53aa to over 1,000aa (see Chapter 2), however, we did not 
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find a correlation between activator size and mCherry signal degradation. Neither did 
mCherry signal correlate with an increase or decrease in epigenetic activity of the 
fusion protein as indicated by luciferase expression. In the future, the use of linkers 
or a p2a sequence to express fluorescent proteins from the same mRNA as the 
epigenetic fusion could help mitigate issues associated with direct fusion of a 
fluorescent tag (Chng et al.; Hadpech et al.).  
Further work should be focused on determining the factors the impact 
fluorescent protein folding dynamics when they are incorporated as fusion proteins. 
We explored shifting the mCherry protein to the N and C termini with no conclusive 
results. For those aiming to visually track fusion proteins within the cell, the factors 
that impact folding will need to be further elucidated, as alternative methods that 
express the fluorescent marker separately will not suffice. Studies in crystallography 
on the changes to beta barrel structure with different N and C terminal fusions 
should be undertaken. 
Given the low detection threshold of 2xd-Broccoli expressed from its original 
plasmid, we surmise that low transfection efficiencies of Gal4_p65, coupled with low 
plasmid copy number and cell loss during staining all contributed significantly to poor 
signal detection of SPiFs by this method. Cloning of 2xd-Broccoli into Gal4_p65 was 
verified by Sanger sequencing before transfection and the construct still increased 
luciferase expression significantly over a mock transfected control, indicating that the 
fusion protein itself was still viable in the cell despite a lack of 2xd-Broccoli detection. 
Likewise, ICC yielded low, although consistent detection of Gal4_p65 via 6XHis tag 
antibody staining. Although both methods have a high level of sensitivity for positive 
cells, neither provided robust detection of average fluorescence in a population with 
low positive cell density. 
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To this end we sought a method of fluorescence detection that pooled cells, 
allowing us to detect expression (fluorescence) in parallel with function 
(bioluminescence). We optimized a plate-reader based assay able to detect 
consistent variations in mCherry expression in parallel with cell density and 
bioluminescence, as an indicator of epigenetic effect in our transgenic HEK293 cell 
line (Tekel, Barrett, et al.). This work provides a facile pipeline for the high-
throughput testing of epigenetically functional fusion proteins used throughout the 
rest of this work.  
 
 
3.4 Methods 
 
3.4.1 Cell culture and transfection  
 
HEK293 Gal4-EED/luc cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% tetracycline-free fetal bovine serum and 
1% penicillin and streptomycin at 37°C in a humidified CO2 incubator. Prior to 
transfection, cells were plated in 12-well culture dishes at 40% confluency (~1.0E5 
cells per well) in antibiotic-free growth medium. Transient transfections were carried 
out by adding 300 µl of DNA/Lipofectamine complexes to each well: 1 µg plasmid 
DNA or ddH2O for mock transfections (10 µL), 5 µL of Lipofectamine LTX (Invitrogen 
#15338100), 285 µL of OptiMEM (Gibco #31985062 ). Plates were spun at 100 xg 
for 5 min to increase transfection efficiency and then incubated at 37°C in a 
humidified CO2 incubator. 
 
3.4.2 Flow cytometry 
 
Cells were passed through a 35 µm nylon strainer (EMS #64750-25). Green 
fluorescent signal from GFP and red fluorescent signal from mCherry were detected 
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on a BD Accuri C6 flow cytometer (675 nm LP filter) using CFlow Plus software. Data 
were further analyzed using FlowJo 10.5.3. One run (∼10 000 live cells, gated by 
forward and side scatter) was completed per sample, allowing us to determine 
median fluorescence within the live cell population. 
 
3.4.3 Fluorescent microscopy 
 
Forty-eight or seventy-two hours post transfection, cellular mCherry or 
GFP/broccoli signal was imaged in culture dishes on a Nikon Eclipse Ti wide field 
fluorescent microscope (MEA53100, filter G2E/C).  
 
3.4.4 Luciferase assays 
 
Luciferase assays were performed using Luciferase Assay Buffer (Biotium 
#30085) according to the manufacturer’s instructions. In brief, a single well of cells 
from a 12 well tissue culture plate was collected per independent transfection. Cells 
were loaded into a Black Costar Clear Bottom 96 Well Plates (Corning #3631). Plates 
were scanned in a microplate reader (Biotek Synergy H1) set to detect 
chemiluminescence. 
 
3.4.5 Broccoli aptamer cloning 
 
The 2Xd Broccoli aptamer sequence housed in pAVU6+27-F30-2xdBroccoli (a 
generous gift from D. Menn) (Filonov et al.) was amplified with Phusion High Fidelity 
DNA Polymerase (New England BioLabs) and primers that facilitated the addition of a 
5’ XbaI and 3’ NotI site. MV14 and the 2xd-broccoli amplicon were both digested 
with FastDigest XbaI and FastDigest NotI (ThermoFisher Scientific) and then ligated 
with T4 DNA ligase (New England Biolabs). 
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3.4.6 Broccoli staining 
 
The lyophilized DFHBI-1T fluorophore (Lucerna, Inc.) was first diluted in 
DMSO to 50mM. For flow cytometry, cells were washed 48 hours post transfection 
with 1XPBS and then trypsinized with Trypsin-EDTA (0.25%), phenol red 
(ThermoFisher Scientific). Harvested cells were incubated in a 1XPBS solution with 
4% 50mM DFHBI-1T for 30 minutes on ice. Cells were resuspended, strained, and 
analyzed via flow cytometry as described above. For microscopy, cells were washed 
48 hours post transfection with 1XPBS. Fresh 1XPBS solution with 4% 50mM DFHBI-
1T was added and cells were incubated on ice for 30 minutes. Cells were 
subsequently visualized in their dish via fluorescent microscopy as described above.  
 
3.4.7 Immunocytochemistry staining 
 
HEK293 cells (~2x106 adherent cells) were initially harvested by washing with 
1XPBS and then trypsinizing them with Trypsin-EDTA (0.25%), phenol red 
(ThermoFisher Scientific). Cells were pelleted at room temperature by spinning at 
1000 rpm for 3 minutes. Cells were then washed twice in ice-cold FACS buffer.  
 After preparing cells, a fixation solution of 4% paraformaldehyde was added 
to the cells and left to incubate for 12 minutes on ice. Cells were then immediately 
pelleted and washed twice in FACS buffer. Cells were then permeabilized with a fresh 
0.5% Triton solution (Sigma-Aldrich) and incubated at room temperature for 30 
minutes. Cells were then pelleted and the permeabilization solution was removed.  
  Cells were then prepared for staining with an AlexaFluor 488 conjugated 
6XHis tag specific antibody (6x-His Tag Monoclonal Antibody (HIS.H8), AlexaFluor 
488, ThermoFisher Scientific). During staining, samples were protected from light as 
much as possible. All staining was done in ice-cold FACS buffer. First, the antibody 
was diluted according to the manufacturer’s protocols in 1XPBS. Diluted antibody 
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was added at a 1:100 ratio to cells suspended in FACS buffer. Cells were incubated 
with the diluted antibody for 30 minutes on ice. After staining, cells were washed 
twice with FACS FB-S buffer. Cells were resuspended, filtered, and run through flow 
cytometry as described above.  
 
3.4.8 Plate reader assay 
 
A single well of cells from a 12 well tissue culture plate was collected per 
independent transfection in 1X PBS. Cells were loaded into 9 wells of a Black Costar 
Clear Bottom 96 Well Plates (Corning #3631). Three wells of cells were used to 
detect mCherry in order to quantify Gal4-AAP proteins. Three more wells were 
loaded with cells and 2X Hoechst 33342 stain (Invitrogen #H3570) to quantify 
nuclear DNA as a proxy for cell density. The final three wells were loaded with cells 
and Luciferase Assay Buffer (Biotium #30085), prepared according to the 
manufacturer’s instructions. Plates were scanned in a microplate reader (Biotek 
Synergy H1) to detect RFP (580 nm - 610 nm), Hoechst 33342 fluorescence (360 nm 
- 460 nm) and chemiluminescence from the same sample in parallel.  
For each sample, luciferase (chemiluminescence), RFP, and Hoechst 33342, 
the average signal from the 1x PBS wells was subtracted from the value for every 
sample well. Next, the average background-subtracted luciferase value for 
untransfected (UT) cells was subtracted from each experimental luciferase value. UT-
subtracted luciferase values were scaled by multiplying each value by [mean UT 
Hoechst / sample Hoechst], then by [mean RFP / sample RFP]. 
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CHAPTER 4 
EXPLORING THE USE OF SYNTHETIC PIONEER FACTORS TO IMPROVE CAS9-
MEDIATED GENOME EDITING IN POLYCOMB HETEROCHROMATIN 
 
4.1 Background 
 
 In Chapter 2, we investigated the ability of Gal4-AAPs to increase gene 
expression at a target site in closed chromatin, but the issue of heterochromatin in 
mammalian genome engineering extends beyond transgene silencing. Prokaryotic 
CRISPR-Cas9 systems are increasingly popular as an easily programmable targeted 
endonucleases for rapid genome editing (Jinek et al.; Gilbert et al.). However, a 
dynamic and growing body of work suggests that heterochromatin inhibits Cas9 
binding and cleavage. As described in Chapter 1, heterochromatin is a dense network 
of proteins and nucleic acids that structurally occludes particular enzymes, such as 
RNA polymerases. Its remodeling is associated with increased accessibility and often 
gene expression. While many efforts to implement Cas9 gene editing in eukaryotic 
cells have been successful, the fluctuating nature of the chromatin environment has 
lead to significant variations in editing efficiency across target sites, posing a 
continued barrier to reliable use (Jensen et al.; Horlbeck et al.; R. M. Daer et al.; X. 
Chen et al.).  
Being bacterially derived, there was initially much skepticism about whether 
or not Cas9 systems would be transferable to eukaryotic chassis, especially 
mammalian ones where the full implications of facile genome editing for medical 
applications might be realized. However, as recently as 2013, Gilbert et al. 
demonstrated the ability of Cas9 to edit mammalian genomes. The robustness of this 
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ability and the parameters that need to be considered to facilitate this editing are still 
an area of active investigation.  
 Before editing can occur, the Cas9-guide RNA complex must bind to the 
target site. Several lines of evidence suggest that heterochromatin may block this 
initial step in editing. Multiple studies have found that off-target binding by nuclease-
null or deactivated Cas9 (dCas9) occurs with a higher frequency in areas of open 
chromatin, as determined by DNaseI hypersensitivity (Singh et al.; Robertson et al.; 
Kuscu et al.). In addition, predictive tools to design guide RNAs yield better binding 
efficiencies when chromatin landscape data are taken into account (Singh et al.). 
 Direct research on the interaction between nucleosomes and Cas9-guide RNA 
complexes support these findings. In a series of in vitro studies using reconstituted 
nucleosomes on synthetic DNA, researchers found that nucleosome-bound DNA 
prohibited binding and cutting by Cas9 (Hinz et al.; Isaac et al.; Horlbeck et al.). 
Complete inhibition found in these studies is most likely a reflection of tighter binding 
between synthetic DNA sequences and nucleosomes as opposed to natural 
sequences which facilitate some level of chromatin breathing (Anderson and Widom; 
Partensky and Narlikar).  
 Within the in vivo context of transgenic mammalian cell lines, Cas9 inhibition 
has been demonstrated in multiple heterochromatin varieties. Our own previous 
work in facultative Polycomb heterochromatin (R. M. Daer et al.) demonstrated the 
sporadic editing capabilities of Cas9 within a short (100-300bp) genomic region. 
While some targets were completely blocked as compared to the open chromatin 
control, others showed only a minimal reduction in editing, suggesting that hyper 
local chromatin dynamics contribute to an overall decrease in editing efficiency (R. 
M. Daer et al.). Likewise, Chen et al. demonstrated a reduction of editing in ectopic 
constitutive HP1-mediated (X. Chen et al.). Again, within a relatively small region 
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(1500bp), all eight of their target sites showed varying amounts of reduction in 
editing as compared to an open chromatin state (X. Chen et al.). Blocking of Cas9-
editing by heterochromatin has even been demonstrated in zebrafish (Y. Chen et al.) 
suggesting that the effects of heterochromatin on Cas9 are pervasive across in vivo 
contexts. 
 Cas9 access to DNA in heterochromatin can be described as sporadic, 
requiring multiple attempts at binding (Kallimasioti-Pazi et al.), and dependent on 
local sequence effects and nucleosome positioning. To this end, several studies have 
found that Cas9 is able to access target sites in closed chromatin and edit effectively 
(Yang et al.; Perez-Pinera et al.; Knight et al.; Polstein et al.). In fact, some groups 
have even used dCas9 as a tool to open up chromatin for increased accessibility, 
although systematic testing in areas of defined heterochromatin is lacking, as 
described in Chapter 1 (F. Chen et al.; Barkal et al.). The combination of these works 
with seemingly opposing conclusions testifies to the complexity of chromatin 
inhibition, and the need for tools that can facilitate editing in all chromatin contexts. 
 Research suggests that chromatin remodeling can reverse heterochromatin 
inhibition of Cas9. In their in vitro studies of the effects of nucleosomes on Cas9 
binding Isaac et al. and Horlbeck et al. successfully reversed inhibition with 
nucleosome-sliding enzymes that improved Cas9 cleavage of DNA previously 
occupied by nucleosomes (Isaac et al.; Horlbeck et al.). In previous work (R. Daer et 
al.), we also attempted to reverse Polycomb-mediated inhibition of Cas9 through 
pretreatment with a targeted p65 activator that is known to significantly increase 
transgene expression in PRC2 heterochromatin. However, at several target sites we 
observed an initial drop in editing accompanied with a significant increase in 
transgene expression (R. Daer et al.). This is most likely due to Polymerase 
crowding, a phenomenon documented as inhibiting Cas9 editing elsewhere as well 
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(Kallimasioti-Pazi et al.), in which the density of polymerases associated with 
artificially high expression levels precludes Cas9 binding.  
 Together these works suggest a targeted approach to the remodeling of 
chromatin that does not necessarily increase expression. Canonically, opening 
chromatin suggests both an increase in accessibility and gene expression. However, 
even within native systems this correlation is not ubiquitous. The Goldilocks state for 
Cas9 in chromatin may be achievable if we can engineer analogues to the devices 
that facilitate “poised” chromatin in natural systems (Bernhart et al.; Lesch and 
Page; Rasmussen et al.). In mammalian systems, this role is filled by pioneer factors 
(see Chapter 1), a unique class of transcription factors that can access DNA in closed 
chromatin and facilitate a transition to an open state (Zaret and Carroll). This 
transition includes the formation of poised chromatin, in which pioneer factors co-
locate repressors and activation-associated histone modifications to a single site 
(Sérandour et al.). In this “door ajar” state, the chromatin can be either pushed 
closed again or fully opened by the recruitment of transcriptional machinery. This 
suggests that pioneer factors may be able to facilitate a low point in the chromatin 
inhibition landscape for Cas9-mediated genome editing. To test this hypothesis, we 
investigated the ability of our Gal4-AAPs (see Chapter 2 for full list) that did not 
increase gene expression to instead increase Cas9-mediated editing efficiency in 
closed chromatin. We hypothesized that these expression-silent fusions were still 
epigenetically active, and that the inherent pioneer function of the Gal4 DNA binding 
domain, coupled with an epigenetic effector may act in a manner similar to native 
mammalian pioneers. To this end, we have named these Gal4-AAP fusions synthetic 
pioneer factors (SPiFs) for their ability to dynamically and separately regulate 
chromatin opening and gene expression activation.  
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In Chapter 2, we used a transgenic HEK293 cell line that allows us to control 
the chromatin state at a transgenic luciferase reporter with the addition of 
doxycycline (Hansen et al.; R. M. Daer et al.). As described in Chapter 2, doxycycline 
induces the accumulation of Polycomb heterochromatin at luciferase, a process that 
is controlled by the two major Polycomb group (PcG) complexes, Polycomb 
repressive complexes 1 and 2 (PRC1/2) (Kahn et al.). PRC2 deposits the repressive 
mark H3K27me3, which has been directly confirmed through chromatin 
immunoprecipitation (ChIP) (R. M. Daer et al.). This histone modification along with 
PcG complex localization induces nucleosome compaction and subsequent gene 
silencing (Jamieson et al.). It is this mechanism that leads to a chromatin state 
inaccessible to polymerases, native nucleosome remodelers, and CRISPR/Cas9 
systems. 
Here we investigate SPiFs as a method for improving Cas9 editing by 
artificially poising chromatin that has been previously inhibited by Polycomb-
mediated heterochromatin (Figure 4.1). Polycomb is a relevant test bed, as PcG 
proteins are critical for gene expression control (Morey, Pascual, et al.; Morey, 
Santanach, et al.) and often involved in oncogenesis (van Lohuizen et al.; Jacobs, 
Scheijen, et al.; Jacobs, Kieboom, et al.; Schuettengruber et al.). They are also 
widely distributed across the genome in gene-enriched regions, where they confer an 
inherited form of gene silencing (Ingham). PcG proteins may also regulate higher-
order chromatin structure and density through long distance interactions between 
PRC1 complexes (Entrevan et al.; Cabrera et al.; Isono et al.; Kundu et al.; 
Schoenfelder et al.). Therefore, Polycomb heterochromatin presents a major barrier 
to genome editing and serves as a good model to investigate the reversal of 
chromatin-mediated Cas9 inhibition. 
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 Cas9-mediated genome editing is an increasingly important tool for 
biotechnology, and eventually medicine. Solving the issues of slow binding, varying 
editing efficiency, and site-specific blockage will be necessary to see Cas9 reach its 
full potential as a tool. Chromatin state plays a major role in each of these issues, 
making our ability to tune chromatin state accessibility for Cas9 critical. Here we 
explore the use of synthetic pioneer factors in optimizing the balance between 
heterochromatin and active euchromatin for Cas9 editing.  
 
 
Figure 4.1: Synthetic pioneer factors increase accessibility to Polycomb 
heterochromatin. In the closed state, PRC2 generates the silencing mark H3K27me3 
(purple M). This complex includes Suppressor of Zeste 12 (SUZ12), Embryonic 
ectoderm development (EED), Retinoblastoma-binding protein (RbAp), and Enhancer 
of zeste 2 (EZH2) (Tiwari et al.; Aoto et al.). PRC1 includes Chromobox protein 
homolog (CBX), Ring finger protein 1b (RING1B), and Polycomb group RING finger 
protein 4 (BMI1) (Tiwari et al.; Aoto et al.). This facultative heterochromatin inhibits 
Cas9 editing, along with DNA and RNA polymerases (X. Chen et al.; R. M. Daer et 
al.). Synthetic pioneer factors containing a Gal4 DNA binding domain (Gal4) and 
activation-associated peptide (AAP) can be used to recruit chromatin-remodeling 
proteins to a specific locus.(Polstein et al.) This targeted opening can induce the 
recruitment of chromatin remodelers (not shown), histone acetyltransferases (HATs), 
and histone methyltransferases (HMTs), that generate activation-associated 
modifications (green A, green M) (Racey and Byvoet; Rea et al.). This induces the 
remodeling of chromatin to support accessible DNA, and a Cas9-permissive state. 
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4.2 Results  
 
 
4.2.1 SPiFs that increase expression do not improve Cas9 editing in closed chromatin 
 
Here we explore the ability of SPiFs to reverse chromatin-mediated Cas9-
inhibition. We used a cost-effective Sanger sequencing based method to evaluate the 
effects of SPiF+Cas9 co-treatment on editing efficiency in closed chromatin (Figure 
4.2). We used doxycycline induction to recruit Polycomb heterochromatin to the 
luciferase transgene as described in Chapter 2. After silencing, we co-transfected 
with a Cas9-sg32 and Gal4-AAP plasmids, both targeted at the luciferase transgene 
(Figure 4.2). Forty-eight hours post transfection, cells were sorted to ensure that 
only cells transfected with both Cas9-sg32 (GFP labeled) and Gal4-AAPs (RFP 
labeled) were used for analysis (Figure 4.2). Genomic DNA was extracted and the 
editing target site was PCR amplified and sequenced using Sanger sequencing. The 
resulting sequences were analyzed using Synthego’s Inference of CRISPR Edits (ICE) 
tool (Hsiau et al.), an open source software that utilizes a modified version of 
Tracking Indels by Decomposition (TIDE) algorithms (Brinkman et al.). This platform 
provides Cas9 editing efficiency data comparable to Next-Gen sequencing analysis 
(Hsiau et al.). 
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Figure 4.2: Synthego ICE method for high quality detection of Cas9 mediated editing 
after SPiF treatment. Silenced Gal4-EED/luc HEK293 cells were co-transfected with a 
Cas9-sgRNA plasmid (target site, g32) and Gal4-AAP plasmid (see Chapter 2). Cells 
were subsequently sorted to select for an entirely GFP/RFP positive population 
(containing both plasmids). Genomic DNA was extracted and editing target site DNA 
was amplified for Sanger sequencing. Sequences were then uploaded to Synthego 
ICE and compared to an unedited control to determine relative editing efficiencies 
across SPiF co-treatment types.  
 
 
We transfected epigenetically silenced Gal4-EED/luc HEK293 cells with a 
pX330_g32 plasmid expressing a Cas9 protein and sgRNA32 (5’ 
CCTCTAGAGGATGGAACCGC 3’), targeted ~100bp downstream of the luciferase 
transcription start site (Figure 4.3a). Site g032 was specifically chosen because 
previous work from our group showed that Cas9-mediated editing at this site was 
almost entirely blocked by heterochromatin but accessible to editing in open 
chromatin (R. M. Daer et al.). This previous work confirmed the inhibition specifically 
of SpCas9 from Streptococcus pyogenes by chromatin (R. M. Daer et al.). In 
Appendix C, we discuss work using the same method outlined in Figure 4.2 to 
establish chromatin inhibition of another Cas9 protein, FnCas9 (F. Chen et al). 
In the same transfection reaction, we added a one of sixteen Gal4-AAP 
plasmids (1:1 stoichiometric ratio), targeted ~350bp upstream of the transcription 
start site (Figure 4.3a). Editing efficiency by SPiF co-treatment type was determined 
via Synthego ICE (Hsiau et al.). We compared editing with SPiF co-treatment to 
Cas9-mediated editing in non-silenced, fully open chromatin (in grey, ~60% editing 
efficiency) and fully silenced, closed chromatin  (in black, ~7% editing) (Figure 
4.3b). We found that Gal4 fusions to the histone acetylase KAT2B and chromatin 
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remodeler SMARCA4 restored editing to levels comparable to open chromatin. AAPs 
associated with significant increases in expression (p65, VP64, and MYB- see Chapter 
2), did not significantly improve editing efficiencies (Figure 4.3b). 
 
 
Figure 4.3: Cas9-editing efficiency in closed chromatin after SPiF treatment. A) 
Gal4_AAPs and Cas9-sg32 are simultaneously targeted to the epigenetically silenced 
luciferase transgene. Gal4 targets the AAP upstream of the editing site to induce 
changes to local chromatin. B) Percent Cas9-mediated editing efficiency at site g032 
by SPiF co-treatment type. SPiF types are arranged by functionality of their AAP 
domains. Efficiency of Cas9 editing in open chromatin is indicated in grey. Efficiency 
of Cas9 editing in closed chromatin is indicated in black. Individual biological 
replicates are shown as single points, while bars represent median percent editing 
efficiency.  
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4.2.2 Indel types induced by Cas9 in re-opened chromatin vary by SPiF co-treatment  
 
To further investigate the specific effects of each SPiF on Cas9-mediated 
editing, we compared the most common types of indels seen for each treatment 
(Figure 4.4). As expected when inducing non-homologous end joining (NHEJ) after 
Cas9-mediated cleavage, shorter indels and single-base pair mutations are most 
prevalent across treatment types. The relative proportions of indel types after SPiF 
treatment closely mirrored those seen in open chromatin (Figure 4.4). We also 
investigated the effects of SPiFs on homologous donor repair (HDR), the alternate 
repair pathway to NHEJ after Cas9-mediated cleavage, using a melt-curve analysis 
method (see Appendix C) (Miyaoka et al.; Smith et al.). 
 
 
Figure 4.4: Most frequent Cas9-induced indels observed in closed chromatin after 
SPiF treatment. The three most common indel varieties induced at site sg032 are 
indicated in reference to the unedited sequence (red). All other indel varieties were 
present at a rate of less than 1% per biological replicate. Each bar represents the 
aggregate of three biological replicates.  
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4.2.3 Cas9 editing range in re-opened chromatin varies by SPiF co-treatment  
 
Editing efficiency is only one Cas9-editing design parameter important to 
genetic engineering. Range of editing at a target site is critical to the subsequent 
repair process (Ochi et al.; Pannunzio et al.). We aggregated data on the range and 
density of indels from NHEJ after Cas9-mediated editing and SPiF co-treatment for 
three biological replicates (Figure 4.5). We found distinct variations in editing ranges 
based on SPiF co-treatment type. Gal4_SMARCA4, while restoring editing efficiencies 
to levels comparable with open chromatin (Figure 4.3b), yields a much narrower 
editing range than that seen in open chromatin (Figure 4.5). Likewise, while not fully 
restoring editing efficiency of Cas9 in closed chromatin, all SPiFs tested did restore 
some level of editing range as compared to closed chromatin (Figure 4.5). 
 
Figure 4.5: Spread and frequency of Cas9-mediated indels with SPiF co-treatment in 
closed chromatin. Range of indels induced by NHEJ after Cas9-mediated cleavage is 
shown for the sg032 target site in luciferase. Ranges of indels induced by NHEJ after 
Cas9-mediated cleavage and SPiF co-treatment are shown by SPiF treatment. 
Function of each SPiF is indicated with colored text according to the key in Figure 4.3 
(red= histone acetylation, blue = transcriptional activation, yellow= chromatin 
remodeling, green= histone H3 methylation). Frequency of editing at each site is 
listed above each nucleotide position. A position was designated as affected by an 
INDEL based on sequence changes relative to the wild type sequence as reported by 
Synthego ICE alignment. Each individual heatmap represents the aggregate of three 
biological replicates.  
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4.2.4 Nucleosome Occupancy and Methylation sequencing (NOMe-seq) can be used 
to evaluate nucleosome position in vivo 
 
After determining that SPiFs can have both a significant impact on chromatin 
accessibility (Figure 4.3b) and expression of the genetic material therein (Chapter 2), 
we wanted to ask what structural changes at the chromatin level contributed to 
these changes from a closed to open chromatin state. We explored in brief the 
depletion of histone modifications associated with Polycomb heterochromatin and the 
accumulation of activation-associated histone modifications deposited by Gal4_AAPs 
or their cofactors (see Appendix C). We did not find a correlation between SPiF 
function (either the induction of gene expression or accessibility) and changes in 
histone modifications; even those SPiFs that appeared to be non-functional induced 
some change to local chromatin modifications (Figure C2).  
 Being the core structural element of chromatin known to inhibit Cas9’s access 
to DNA (Horlbeck et al.; Isaac et al.; Hinz et al.) we wanted to investigate changes in 
nucleosome density and position at site sg032 before and after SPiF treatment. 
Several methods exist for broadly determining nucleosome occupancy (Meyer and 
Liu). DNase sensitivity assays utilize an exonuclease to cleave exposed DNA in order 
to identify areas of open chromatin (Madrigal and Krajewski); however this approach 
is typically used to characterize chromatin density across large genomic regions as 
opposed to high-resolution nucleosome mapping. Similarly, ATAC-seq and DIVA-seq 
utilize the insertion of transposons or viral DNA to identify areas of chromatin with 
greater accessibility (Kumasaka et al.; Timms et al.). MNase-seq utilizes a 
Micrococcal endonuclease that directionally digests DNA until an obstruction, such as 
a nucleosome, is reached, allowing for higher-resolution mapping of local 
nucleosome density (Luo et al.; Nikitina et al.). While this method provides relative 
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sequence lengths based on average nucleosome occupancy, direct sequence 
mapping is difficult. A relatively new method known as Nucleosome Occupancy and 
Methylation sequencing (NOMe-seq) provides high-resolution data on nucleosome 
occupancy that can be directly mapped to DNA sequence position (Rhie et al.; Piao et 
al.; Lay et al.). 
 NOMe-seq utilizes a non-canonical GpC methyltransferase (M.CviPl) to 
methylate GpC sites that are unbound by nucleosomes, or other large obstructions 
such as transcription factors (Figure 4.6) (Rhie et al.). Bisulfite conversion induces 
mutations at unmethylated cytosines, allowing for direct mapping of nucleosome 
position (mutated cytosine bases) to the original sequence of interest (Figure 4.6). 
We are currently optimizing NOMe-seq as an approach to map nucleosomes at the 
luciferase transgene in open chromatin, closed chromatin, and SPiF-treated closed 
chromatin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Nucleosome Occupancy and Methylation sequencing (NOMe-seq) can be 
used to determine nucleosome position after SPiF treatment in closed chromatin. 
Treated cells are lysed such that chromatin can be fixed and sheared into lengths of 
less than 1 kilobase. Treatment with the M.CviPl GpC methyltransferase induces 
methylation of exposed cytosine bases. In subsequent bisulfite conversion, 
unmethylated cytosines are converted to uracil, inducing mutations relative to the 
reference sequences after Sanger sequences. These regions of single base cytosine 
to thymine mutations indicate the presence of a nucleosome. 
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4.3 Discussion 
 
Here we investigated the ability of SPiFs to improve Cas9-mediated editing in 
induced Polycomb heterochromatin. We hypothesized that a poised, permissive state 
between hyper compacted closed chromatin and active open chromatin would allow 
for increased editing efficiency by Cas9. Previous work (R. Daer et al.) with the SPiF 
Gal4_p65 established that gene expression activity and exonuclease accessibility 
must be considered as two separate parameters when opening chromatin. Hyper 
expression induced by Gal4_p65 actually reduced initial editing by Cas9 at several 
sites (R. Daer et al.). Further work should be done to fully understand the 
mechanism behind Polymerase crowding and inhibition of Cas9. 
 From our panel of SPiFs we were able to identify several “silent” SPiFs that do 
not increase local gene expression but do increase accessibility to the DNA for Cas9. 
Understandably, a Gal4 fusion to the chromatin remodeler domain SMARCA stored 
editing levels to those observed in open chromatin. However, the range of editing 
was less than that observed in other SPiF treatments, indicating that nucleosomes 
were potentially shifted rather than displaced. Further investigation into local 
nucleosome position after each treatment will be needed to fully assess changes to 
local chromatin and their impact on Cas9 editing.  
 The second SPiF that significantly increased Cas9 editing in closed chromatin 
contained a KAT2B histone acetylase domain. ChIP to assess the collocation of 
remodelers or other transactivators recruited by KAT2B should be performed to fully 
understand the mechanism behind opening. In general, functional assays to evaluate 
the chromatin landscape after treatment with each SPiF should be performed in order 
to understand the differences in chromatin composition that lead to either an 
active/inaccessible, inactive/accessible, or even active/accessible state. ChIP data in 
Appendix C suggest that histone modifications alone may not be predictive of one 
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state or the other. ChIP for polymerase colocation and full nucleosome mapping 
should be pursued. By looking at direct indicators of transcription and chromatin core 
structure we should gain more insight into Cas9 permissive chromatin architecture. 
These insights will in turn improve our ability to engineer mammalian cells with Cas9 
systems.  
 Once Cas9 has access to its target DNA, other parameters become critical for 
effective editing. The range and variations of indels impact final editing outcomes. 
HDR and NHEJ pathways are in competition within the cell after Cas9 induces a 
strand break. Range, location, and fidelity of cleavage all impact which pathway will 
triumph (Miyaoka et al.). Whether the final desired outcome is a single base deletion 
or a full gene replacement, impacts the tuning of local chromatin state that will be 
required to reach acceptable levels of editing efficiency and range. Likewise, the 
ability to engineer accessibility without increasing expression levels will be of great 
value to any applications in a therapeutic setting. Genes targeted for therapeutic 
editing are often producing an undesirable gene product, expression of which should 
not be increased. 
Refined opening of chromatin for Cas9 has several advantages in an in vivo 
setting. Whereas epigenetic drugs can open chromatin, site-specific approaches will 
not have the same broadly disruptive, unpredictable effects (Harrison). Many 
candidate diseases for genetic therapies such as neurodegenerative disorders or 
cancer are already characterized by unstable or disordered chromatin landscapes; 
avoiding compounding factors to epigenetic dysregulation is key (Verma; Coppedè; 
Kocerha and Aggarwal). Similarly, while Cas9 inhibition is not complete in closed 
chromatin, it is dose-dependent (Kallimasioti-Pazi et al.). Kallimasioti-Pazi et al. 
showed that by increasing Cas9 dosage, they were able to increase the speed and 
efficiency of Cas9-mediated cleavage in closed chromatin (Kallimasioti-Pazi et al.). 
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However, in many in vivo applications increasing Cas9 load will not be an option to 
overcome heterochromatin inhibition due to potential adverse host immune reactions 
(Hartweger et al.; Charlesworth et al.). Co-treating with effective epigenetic 
modifiers or modifying Cas9 directly with such pioneer domains, may allow us to 
reap the full benefits of its editing capabilities regardless of chromatin. 
 
4.4 Methods  
 
 
4.4.1 Cell culture and transfection 
 
Cell culturing, silencing, and transfection of Gal4-EED/luc HEK293 cells were 
carried out as described in Chapter 2.  
 
4.4.2 Aria cell sorting 
 
Silenced and transfected Gal4-EED/luc HEK293 cells were collected 72 hours 
post transfection with Cas9_sg032 via standard trypsinization. Cells were diluted in 
ice-cold PBS + 20% FBS to ~10E7 cells per mL. At least 100,000 cells per sample 
were collected for genomic DNA extraction on a BD FAS Aria IIu Cell Sorter, with 
gate settings to collect only live cells with RFP/GFP double positive expression.  
 
4.4.3 CRISPR editing analysis via Synthego ICE 
 
 Cells were co-transfected SPiF plasmids and pU6-(BbsI)_CBh-Cas9-T2A-EGFP 
(DNASU UnSC00746685) containing sgRNA sg032. Seventy-two hours post 
transfection, cells were harvested via standard trypsinization and run through Aria 
cell sorting. 
After cell sorting, genomic DNA was extracted using a QIAamp DNA Mini Kit 
(Qiagen). The editing target region was PCR amplified using GoTaq 2x Mastermix 
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(Promega) and primers 196 (5’ cggaggacagtactccgctc 3’) and 198 (5’ 
ggcgttggtcgcttccggat 3’) with the following cycling parameters: Cycle: 98°C  /30 
seconds, 35X (98°C/10 seconds, 67°C/ 30 second, 72°C/1min), 72°C  10 minutes, 
hold at 4°C. Amplicons were submitted for purification and Sanger sequencing to 
GeneWiz according to their protocols.  
Once sequences were returned, they were uploaded alongside an unedited 
control sequence to Synthego’s ICE Tool (https://ice.synthego.com/#/).  Synthego 
ICE calculates percent editing across a sequence as well as frequency of indel 
variants across the range of edited sequence.  
 
4.4.4 Nucleosome Occupancy and Methylation sequencing   
 
NOMe-seq was performed using Active Motif’s NOMe-seq kit (Active Motif, 
#54000). The manufacturer’s protocol was followed, culminating in target region 
amplification via PCR and Sanger sequencing as described above. In brief, seventy-
two hours post-transfection with an individual SPiF construct, cells are harvested and 
fixed using formaldehyde. This was followed by cell lysis, nuclei collection, and 
sonication to prepare strands of chromatin less than 1Kb long. The sheared 
chromatin was then treated with a GpC methyltransferase that non-canonically 
methylates cytosines. Chromatin cross-linking was reversed and DNA was purified 
for bisulfite conversion. Bisulfite conversion mutates the methylated cytosines such 
that the sites of methylation can be detected via sequencing. After bisulfite 
conversion, the DNA was desulfonated and purified for PCR and Sanger sequencing 
as described above.  
 The resulting sequences were analyzed for homology to an untreated control 
using Methyl Viewer (http://dna.leeds.ac.uk/methylviewer/), which visually indicates 
alterations to methylation. As nucleosomes preclude the GpC methylase, areas 
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lacking in conversion indicate the presence of a nucleosome; in this way the 
sequence mutations allow for visual mapping of nucleosomes across the sequence.  
 
4.4.5 ChIP-qPCR  
 
Chromatin immunoprecipitation qPCR was carried out as described in Daer et. 
al (R. Daer et al.). In brief, seventy-two hours post-transfection, cells were 
harvested for fixation with 1% formaldehyde (Thermo Fisher Scientific) in 1x 
Dulbecco’s PBS. The reaction was quenched with 125 mM glycine (Sigma-Aldrich), 
followed by four washes with 1x PBS and Pierce Protease Inhibitors (Thermo Fisher 
Scientific).   
 Next, chromatin was prepared by lysing the cells and nuclei. The resulting 
chromatin was sonicated and diluted for immunoprecipitation with anti-H3K27me3 
antibody (07−449, Millipore) or anti-H3K4me3 (ab8580, Abcam). After 
immunoprecipitation, crosslinking was reversed and DNA was prepared using the 
Genelute PCR Cleanup Kit (Sigma-Aldrich). 
 Quantitative PCR for the target site was performed with SYBR Green 
Mastermix (ThermoFisher Scientific) and previously published primers for the sg032 
site in luciferase as well as a GAPDH control (R. Daer et al). To analyze ChIP-qPCR 
assay data, averages and standard deviations were calculated for each of 3 replicate 
IPs from a single chromatin preparation. For each cell/ treatment data set, %IP DNA 
for luciferase and GAPDH were normalized to %IP DNA for GAPDH.  
 
4.4.6 Homology-directed repair melt curve analysis 
 
Gal4-EED/luc HEK293 cells were silenced and transfected with SPiF constructs 
as described previously. Three days after initial transfection, cells were transfected 
again with Cas9_sg032 and a single stranded DNA oligo (ssODNA) with 
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complementarity to the sg032 cut site (5’ 
ggcgccattctatcctctagaggatggaacataaagctgatgcgctggagagcaactgcataaggctatgaa 3’ ). A 
ratio of 1ug Cas9 plasmid to 2ug ssODNA was used per transfection. Seventy-two 
hours post transfection, cells were harvested via standard trypsinization and genomic 
DNA extraction was performed using a QIAamp DNA Mini Kit (Qiagen).  
 Quantitative PCR was performed with SYBR Green Mastermix (ThermoFisher 
Scientific) and primers for the sg032 insertion site (p360: 5’ 
CGGCGCCATTCTATCCTCTA 3’ , p361: 5’ ATTCCGCGTACGTGATGTTC 3’) as well as 
primers for an unaffected TBP locus (TBPF: 5’ CAGGGGTTCAGTGAGGTCG 3’, TBPR: 5’ 
CCCTGGGTCACTGCAAAGAT 3’). The following cycling parameters were used: 95°C/ 
3 min., 40x (95°C/ 10 sec., 57°C/ 10 sec, 72°C/ 10 sec), 72°C/ 3 min.  
To analyze the data, we looked at the negative first derivative of the melting 
stage plot, which shows fluorescence (y-axis) over temperature (x-axis). Each 
sequence variant (unedited vs. those containing the ssODNA insert) melts at a 
different temperature, leading to distinct drops in the curve at different temperature 
intervals. By looking at the negative first derivative of this plot, we can see distinct 
peaks that correspond to each drop in the original plot. To compare the untreated to 
the treated samples, calculate  
(PeakmaxCRISPR / Peakmaxref) / (Peakmaxuntreated / Peakmaxref) where the reference peaks 
(from the TBP melt curves) serve as loading controls. These values can then be 
compared across SPiF+CRISPR treatment types. 
 
4.4.7 FnCas9 sgRNA cloning  
 
Guide RNAs were cloned into the U6_FnCas9_sgRNA plasmid to direct FnCas9 
to the silenced luciferase target site. Two sgRNA oligos with synthesized with 
overhangs for AarI cloning (in bold) (g32 F oligo Aarl: 5' 
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ACCGCCTCTAGAGGATGGAACCGC 3'; g32 R oligo Aarl: 5' 
AAACGCGGTTCCATCCTCTAGAGG 3'). These oligos were phosphorylated and 
annealed at 37°C for 30 min with T4 PNK (New England Biolabs). Following 
annealing, the oligo dimers and the U6_FnCas9_sgRNA backbone were both digested 
with AarI (ThermoFisher Scientific) and ligated with T4 ligase (New England Biolabs).  
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CHAPTER 5 
DISCUSSION 
 
In this work we investigated the utility of synthetic pioneer factors (SPiFs) for 
controlling chromatin state in mammalian cells. We sought to control local chromatin 
compaction with two primary goals in mind, 1) epigenetically modulating gene 
expression and 2) increasing accessibility for genome editing tools such as 
CRISPR/Cas9.  
Epigenetic control of gene expression has a wide range of uses. Here we 
focused on the reversal of transgene silencing to improve long term stability of 
exogenous gene expression in engineered cell lines. Gene expression control tools 
can themselves be incorporated in genetic devices, such as toggle switches or 
repressilators (Kramer et al.; Perez-Carrasco et al.; Rabajante and Babierra). In 
Chapter 2, we demonstrated the potential of the MYB TAD to be used as a toggle 
device under the control of small molecule drugs. Changes in MYB-induced 
expression were extremely rapid (2-3 hours) with the addition of celastrol, making it 
a good candidate for a switch in modular device design within mammalian cells. 
Beyond in vivo engineering devices, epigenetic gene expression control has 
the potential to be used in medical applications from the production of model cell 
lines for research to in situ therapeutics. The same devices that can alter gene 
expression to match the profile of disease cell types for drug screens could be used 
to tune expression control to alter cell fate (Black et al.) either to reprogram 
diseased cells to a health state or control development for the growth of artificial 
tissues and organs. While in situ therapeutics and major organ development are still 
unrealized applications of epigenetic modulators, the refinement of these tools sets 
the groundwork for realizing these goals. 
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Secondly, the engineering of accessible chromatin, while less well researched, 
may be equally critical to the development of both reliable mammalian synthetic 
biology devices and in situ (epi)genetic therapeutics. Reliable access to DNA opens 
up the entire genome for editing and increases efficiency of editing at low 
concentrations of Cas9 protein (Kallimasioti-Pazi et al.), an important parameter for 
avoiding adverse immunological effects (Charlesworth et al.). Investigation of 
chromatin accessibility will also improve our general knowledge of chromatin 
structure, which is rapidly changing as the role of RNAs in chromatin is found to be 
increasingly important (Y. Li et al.; Guttman; Huang et al.) and our knowledge of the 
phase-like nature of chromatin develops (S. Liu et al.; Erdel and Rippe; Gibson et 
al.). 
In Chapter 1 we outlined the set of potential tools available for the targeted 
modulation of chromatin. Synthetic biologists continue to use naturally occurring 
molecules as modular parts. Mammalian cells provide several mechanisms as 
inspirations for chromatin opening devices. These mechanisms are interconnected 
and interdependent, implying that more sophisticated design should utilize several 
mechanisms either sequentially or in parallel. Currently, the depth of these 
interconnections is underexplored and not yet amenable to engineering. Future work 
should aim to investigate co-dependence of various chromatin-opening mechanisms 
and underexplored mechanisms for controlling chromatin state, such as canonical 
pioneer factors.  
In Chapters 2, 3, and 4 we explored the capabilities of a panel of synthetic 
pioneer factors (SPiFs) that utilized the functions for opening chromatin outlined in 
Chapter 1. We began in Chapter 2 by investigating the ability of these SPiFs to 
increase transgene expression in induced Polycomb heterochromatin. We found that 
SPiFs with transcriptional activation domains were the only group able to significantly 
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increase transgene expression, and that this increase in expression can be sustained 
after transient induction. This finding has implications for the engineering of stable 
mammalian cell lines. 
 Furthermore, among these activating SPiFs, the MYB TAD provides a novel 
tool for synthetic biologists. Its utility goes beyond that of simple gene expression 
enhancement, as its activating function can be rapidly controlled by the small, 
minimally toxic drug celastrol. The MYB TAD is functional when fused to multiple 
different DNA binding domains including Cas9, and can increase transgene 
expression in Polycomb heterochromatin as well as endogenous heterochromatin. 
Our results also suggest a cooperative, complex mechanism for chromatin opening 
as all activating SPiFs have no inherent catalytic activity and thus rely on the 
recruitment of cofactors to activate gene expression in closed chromatin. The identity 
of these cofactors and the specific changes to chromatin structure that each SPiF 
induces should be evaluated in future work. This could be achieved through a 
combination of ChIP at the target site and siRNA knockdown of putative interaction 
partners. The development of MYB as a new tool for gene expression control in 
mammalian cells warrants further investigation for its utility in more complex devices 
and endogenous settings. Future work should focus on incorporating MYB into multi-
activator fusions such as VPR or SunTag (Z. Li et al.; Guo et al.; Papikian et al.). The 
ability of MYB to activate endogenous genes for cell programming should be 
investigated as well, to understand its transferability to in situ applications. 
 To facilitate our investigation of SPiFs, we needed to develop a robust method 
to assay their presence in parallel with their functionality. We developed such an 
assay as described in Chapter 3, allowing us to visualize SPiF protein production in 
combination with their ability to activate gene expression in induced Polycomb 
heterochromatin via luciferase expression. Our work in this chapter also indicated 
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dynamic inconsistencies in beta barrel fluorescent fusion tag signal expression across 
SPiF types and sampling date. This suggests the need to further investigate 
individual protein level differences in folding across parameters such as cell cycle, 
fusion protein localization, and construct configuration. Mitigation of signal variation 
was achieved here by pooling cells, as opposed to reading signal from individual 
cells. Fusion protein tag folding dynamics warrants further investigation due to its 
ubiquitous use in synthetic biology and the common under reporting of negative 
results. 
 Being able to visualize SPiFs and having quantified their ability to activate 
gene expression in closed chromatin, we turned to the other central issue with 
heterochromatin in engineering mammalian cells. A growing body of literature 
supports the hypothesis that chromatin prohibits reliable access to DNA by 
CRISPR/Cas9 (Daer et al.; Hinz et al.; Horlbeck et al.; Isaac et al.). Here, we show 
this to be the case for the newly discovered FnCas9 as well as canonical SpCas9 
(Chen et al.). Development or discovery of new Cas9 species should be accompanied 
by experimental evaluation of the effects of eukaryotic chromatin on these 
nucleases. For example, the recently discovered CasX protein is significantly smaller 
than SpCas9 (J.-J. Liu et al.). Will this smaller protein have a harder time pushing 
nucleosomes out of the way to access DNA or an easier time slipping in between 
them? With the use of cell sorting and cheap, effective editing efficiency analysis via 
Synthego ICE or similar algorithms as we present here, high-throughput pipelines to 
assay the effects of chromatin on Cas nucleases could easily be implemented for 
rapid evaluation of new enzymes.  
We hypothesized that some of our SPiFs that did not activate gene expression 
may still be functionally altering chromatin because of their inherent pioneer 
function. This function may improve access to DNA without directly inducing gene 
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expression, as many canonical pioneer factors do in creating a poised chromatin 
state (Bernhart et al.; Iwafuchi-Doi and Zaret). Indeed we identified two SPiFs in our 
panel, Gal4_KAT2B and Gal4_SMARCA4 that significantly increased Cas9 editing 
efficiency in closed chromatin without activating gene expression. These “silent” 
SPiFs are potentially useful for engineering or in vivo applications where ramping up 
target gene expression is undesired. Increasing expression before editing could 
destabilize metabolic circuits in the context of an engineered cell line, or potentially 
be highly detrimental in a gene therapy context where the therapy itself aims to 
remove a mutant gene that produces toxic product. Inducing accessibility without 
gene expression enhancement could thus be highly valuable.  
We also investigated changes to the types and range of indels induced by 
Cas9 with SPiF co-treatment. Being able to tune these parameters could provide 
another layer of control for Cas9 in chromatin. Future directions of this work should 
primarily be focused on characterizing the chromatin that is responsible for these 
differences in editing efficiency and range. ChIP to evaluate the nature of a poised 
state based on specific histone modifications and colocalization of 
repressors/activators could tell us a great deal about how to induce this state and to 
what degree it mirrors natural poised chromatin. NOMe-seq mapping of nucleosomes 
before and after SPiF treatment should be completed. Future studies should also test 
more domains related to KAT2B and SMARCA4 to help elucidate the mechanism 
behind their ability to increase accessibility. Crystallography to examine their direct 
interactions with nucleosomes could also be informative. 
Over all we conclude that there is a distinct difference between active and 
accessible chromatin as induced by SPiFs, and most likely by other targeted 
epigenetic modifiers and activators. Accessibility and gene expression enhancement 
can both occur in isolation from one another due to a variety of mechanisms. This 
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difference warrants closer investigations of chromatin before and after treatment 
with targeted epigenetic modifiers to elucidate the structural differences between 
these states. This work suggests the development of distinct tool kits in chromatin 
engineering for inducing both accessible and active states separately from one 
another, as each has its own unique utility to synthetic biologists. In order to achieve 
this goal, we must first define what each state looks like based on its basic chromatin 
structure. To what degree are histone modifications predictive of either condition? 
What cofactors induce prohibitive crowding or stabilize an accessible state? To what 
degree are larger forces such as phase separation playing a role in the accessibility 
to certain loci and the longevity of any induced changes to the chromatin therein? 
Characterization of induced open chromatin states, rather than just their outcomes 
will be the key to furthering our ability to engineer such complex biological 
microenvironments as chromatin.  
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Table A1. Detailed description of AAP interaction partners. Interaction partners are 
grouped by general function: histone acetyltransferases (HATs or HAT complex 
subunits), histone deacetylases (HDACs), histone methyltransferases (HMTs or HMT 
complex subunits), coactivators, kinases, ubiquitinase, DNA methyltransferases 
(DNMTs), and non-catalytic structural proteins. Chromatin modifications (histone 
post-translational modifications and DNA methylation) are listed next to each 
enzyme as appropriate. This table exceeds dimensions of this file and can be 
accessed at https://www.biorxiv.org/content/10.1101/487736v1.supplementary-
material.  
 
 
 
Table A2. AAP accession numbers and primers. Capitalized nucleotides indicate 
overhangs for the addition of XbaI and NotI sites for cloning. 
 
AAP UniProt 
ID 
Isoform  NCBI RefSeq Amplification primers (5’ .. 
3’) 
VP64 
(4xVP16) n.a. - - 
F: 
CCTTATCTAGAgacgctttggacgac
ttcga 
R: 
CTTAGCGGCCGacaacatgtccaag
tcgaagt 
(NKκB)-
p65 Q04206 - NM_001145138.1 
F: 
CCTTATCTAGAtacctgccagataca
gacga 
R: 
CCTTAGCGGCCGatctcagccctgct
gagtcag  
MYB P10242 
Isoform 1 
P10242-1 NM_005375.2 
F: 
GGCCTTATCTAGccagctgccgcag
ccattca 
R: 
AATTAGCGGCCGcccacccggggta
gctgcat 
  153 
ATF2 P15336 
Isoform 1 
P15336-1 NM_001256090.1 
F: 
CCTTATCTAGAgagatgacactgaa
atttgg 
R: 
CCTTAGCGGCCGaggatcttcgtta
gctgctc  p300 Q09472 Q09472-1 NM_001429.3 gBlock from IDT 
KAT2B 
(PCAF) Q92831 Q92831-1 NM_003884.4 
F: 
CCTTATCTAGActcaaccagaaacc
aaacaa  
R: 
CCTTAGCGGCCGatttagctcacatc
ccatta  KMT2A 
(MLL1) 
Q03164 Isoform 1 
Q03164-1 
NM_005933.3 gBlock from IDT 
KMT2C 
(MML3) 
Q8NEZ4 Isoform 1 
Q8NEZ4-1 
NM_170606.2 gBlock from IDT 
KMT2D 
(MLL2, 4) 
O14686 Isoform 1 
O14686-1 
NM_003482.3 gBlock from IDT 
KMT2E 
(MLL5) Q8IZD2 
Isoform 1 
Q8IZD2-1 
NM_182931.2 (variant 
1) 
F: 
GCGCTCTAGAaatttggataaagag
agggc 
R: 
AATGCGGCCGcttcattactaatagg
agtt 
SETD1A 
(SET1) O15047 O15047-1 NM_014712.1 
F: 
CCTTATCTAGAaagaagctccgattt
ggccg 
R: 
CCTTAGCGGCCGagtttagggagcc
ccggcagc  
SETD1B 
(SET1B) 
Q9UPS6 Isoform 1 
Q9UPS6-1 
No RefSeq number gBlock from IDT 
SETD7 
(SET7/9) 
Q8WTS6 Q8WTS6-1 NM_030648.2 gBlock from IDT 
PRMT5 O14744 
Isoform 1 
O14744-1 NM_006109.4 
F: 
ATGCTCTAGAatggcggcgatggcg
gtcgg 
R: 
ATGCGCGGCCGcgaggccaatggt
atatgagc  
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FOXA1 P55317 P55317-1 NM_004496 
F: 
GGCTCTAGAatgttaggaactgtgaa
gatgga 
R: 
ATTGCGGCCGccaaggaagtgttta
ggacgg  
SMARCA4 
(BRG1) P51532 
Isoform 1 
P51532-1 
NM_001128844.1 
(variant 2) 
F: 
CCTTATCTAGAatgtccactccagac
ccacc 
R: 
CCTTAGCGGCCGgctgctgtccttgt
acttga  
Table A3. dCas9-MYB sgRNA targeting sequences. The targeting sequences for g46, 
g31, g32, and g25 have been used in our previous work. 
 
Transgene Cell line Target 
Name 
Targeting Sequence 
Tk-Luciferase  HEK293 Gal4-EED/luc g46 5’ cctgcataagcttgccacca 
3’ 
g31 5’ 
cgaggtgaacatcacgtacg 
3’ 
g32 5’ 
cctctagaggatggaaccgc 
3’ 
g25 5’ accgtagtgtttgtttccaa 
3’ 
CMV-GFP 
 
HEK293 GFP (Chang 
Liu, UC Irvine, 
L1 5’ ctctgtcacaggactcagcc 
3’ 
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unpublished) L2 5’ 
gggcggtaggcgtgtacggt 
3’ 
L3 5’ cactggtgtcgtccctattc 
3’ 
L4 5’ cttcttcaagtccgccatgc 
3’ 
 
 
Table A4. Publicly accessible plasmids used in this study. Annotated sequences can 
be viewed online in the Haynes lab Benchling collection “DNA-Binding Fusion 
Transcriptional Regulators” at https://benchling.com/hayneslab/f_/5wovkOaK-gal4-
dna-binding-fusion-transcription-regulators/?sort=name.  
 
 
Name DNASU Accession # 
MV14 - 
MV14_VP64 HaCD00812388 
MV14_p65 HsCD00812387 
MV14_MYB - 
MV14_ATF2 HsCD00833013 
MV14_p300 HsCD00833014 
MV14_KAT2B HsCD00833015 
MV14_KMT2A HsCD00833016 
MV14_KMT2C HsCD00833018 
MV14_KMT2D HsCD00833017 
MV14_KMT2E - 
MV14_SETD1A HsCD00833019 
MV14_SETD1B HsCD00833020 
MV14_SETD7 HsCD00833021 
MV14_PRMT5 - 
MV14_FOXA1 - 
MV14_SMARCA4 HsCD00833022 
pX330g_dCas9_MYB - 
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Table A5. Primers for qPCR to quantify Gal4-AAP mRNA 
Target Amplification primers (5’... 3’) 
mCherry (Gal4-AAP transcripts) F: gctccaaggcctacgtgaag 
R: aagttcatcacgcgctccca 
TBP (housekeeping gene) F: caggggttcagtgaggtcg 
R: ccctgggtcactgcaaagat 
 
 
Figure A1. Additional trials of time course experiments with Gal4-AAP-expressing 
cells. Experiments were performed as described for Trial 1 in Figure 5A. Asterisks (*) 
= p < 0.05 for mean values greater than the mean for the “No activator” negative 
control sample. 
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Figure A2. Annotated motifs within the MYB protein. Annotated motifs within the full-
length MYB protein (AAA52032.1). From left to right: Dispersed nuclear localization 
signal (NLS) (M1-Q200; in light blue); Casein kinase II phosphorylation sites that 
reduce MYB DNA binding when phosphorylated and D152V mutation site that nullifies 
limited MYB pioneer function by disrupting DNA binding site recognition (S11, S12, 
D152; in red); Repeat regions (R1-R3) that facilitate MYB binding to its recognition 
element (G34-L86, N87-L138, N139-M189; in purple); Transcription activation 
domain (P275-W327; in green); Core acidic domain of TAD  that facilitates 
interaction with CBP/p300 (D286-L309; in bright green); M303V mutation that 
disrupts p300 recruitment and thus, activation by MYB (M303; in red; Leucine zipper 
domain that interacts with other cellular proteins (L383-L403; in orange); Negative 
regulatory domain (V512-P566; in red), removal of which increases MYB-mediated 
expression increase. 
 
 
Figure A3. MTT cell viability assays. An MTT ((3‐(4,5‐Dimethylthiazol‐2‐yl)−2,5‐
diphenyltetrazolium bromide)) cell viability assay to determine the effects of C646 
and Celastrol on cell survival was performed as described previously by Godeshala et 
al. [S20]  In brief, Gal4-EED/luc cells were treated with either C646 or Celastrol 
diluted at different concentrations in Gibco DMEM high glucose. Cells were incubated 
with the drugs for six hours before being washed and cultured for 3 hours in drug 
free medium containing MTT reagent solution. Finally, cells were incubated with 
methanol:dimethyl sulfoxide (1:1) at room temperature for 30 minutes and mixed 
thoroughly before absorbance was read at 570 nm. The relative cell viability (%) was 
calculated from [ab]test/[ab]control × 100%. For each sample, the final 
absorbance/cell viability was reported as the average of values measured from three 
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wells in parallel. Bars = standard error. We found no significant impact on cell 
viability after treatment with celastrol or C646 at any of the concentrations tested.  
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Figure B1. Determination of plate reader detection limits for Hoechst and RFP 
(mCherry). Samples of varying signal intensity were used to determine the linear 
range of signal detection for the Biotek Synergy H1 plate reader using the settings 
described in our report. (A) To prepare samples for the Hoechst channel (360-460 
nm), HEK293 cells were grown to 90% confluency in a 12-well plate, collected, 
stained with varying concentrations of dye. Dots show mean values from triplicate 
cell samples (bars, standard deviation). The maximum and minimum Hoechst signal 
values from the plate reader data from Figure 5 are marked with dotted lines. (B) 
Samples for the RFP channel contained 5.0 to 62.0 µM 6-histidine-tagged 
recombinant PcΔ protein diluted in 1X PBS (200 µL per well). PcΔ was over-
expressed in E. coli cultures and purified on a nickel-column as described in detail in 
Tekel et al. Dots show mean values from triplicate protein samples (error bars, 
standard deviation). (This figure and its legend are reprinted here with permission 
from ACS Publications, Copyright © 2018 American Chemical Society Publications) 
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Figure C1: Induced Polycomb heterochromatin inhibits FnCas9. A) We targeted both 
SpCas9 and FnCas9 (Chen et al.) to site sg032 in our luciferase transgene. B) We 
compared editing by both Cas9 exonucleases in closed chromatin (silenced Gal4-
EED/luc HEK293 cells) and open chromatin (Luc14 HEK293 cells). Both Cas9 
exonucleases showed a relative reduction in editing in closed chromatin as compared 
to open chromatin. SpCas9 is a more robust exonuclease in both chromatin states. 
C) Variety and spread of indels from NHEJ after FnCas9-mediated cleavage is 
significantly higher in open chromatin as compared to closed chromatin.  
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Figure C2: Changes in local histone modifications are not predictive of SPiF function. 
A) We performed chromatin immunoprecipitation (ChIP) qPCR across the sg032 
editing site and GAPDH (control) in Gal4-EED/luc HEK293 cells, to determine 
changes in two local histone modifications after SPiF treatment. B) For all SPiFs that 
we treated cells with before ChIP-qPCR there was a reduction in repression-
associated H3K27me3, a mark directly deposited by PRC2 in our inducible Polycomb 
system. DMSO serves as a null-treatment control, indicating baseline levels of 
H3K27me3 in silenced Gal4-EED/luc HEK293 cells. While p65 induces increased 
levels of expression (Chapter 2), ATF, KMT2C and KMT2D do not, although they do 
reduce repression associated histone modifications. C) All four SPiFs increase 
H3K4me3. KMT2C and KMT2D directly deposit this modification, while p65 has no 
direct catalytic activity on histones. Again, despite differences in functionality, all 
SPiFs modify the local histone code as compared to a DMSO control.  
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Figure C3: Melt curve analysis method for the detection of homology directed repair 
(HDR) after Cas9-mediated cleavage. Melt curve analysis allows for low cost 
detection of ssDNA template insertion into a target site. We transfected silenced 
Gal4-EED/luc HEK293 cells with SPiF constructs and subsequently Cas9-sgRNA 
plasmids along with ssDNA target site template DNA. Seventy-two hours post 
transfection, we harvested cells and extracted genomic DNA. These cells are a mixed 
population of edited and unedited cells. The target site was amplified with 
quantitative PCR and the resulting melt curves were compared. Larger sequences 
melt at higher temperatures allowing us to assess insertion rates of the ssDNA 
template. TBP was amplified for each sample as a loading control.  
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Figure C4: Replicating the results of Daer et al., 2017 with HDR melt curve analysis. 
In Daer et al, 2017, we found that SpCas9 editing is significantly reduced in closed 
chromatin and partially silenced chromatin as compared to an open chromatin 
control. These results were determined via SURVEYOR assay. Here, we attempted to 
replicate those results using HDR melt curve analysis in order to vet the assay. We 
targeted site sg032, which previously showed substantial inhibition in closed 
chromatin, but was still accessible to Cas9 in open chromatin. The figure above 
shows a recapitulation of these results using HDR melt curve analysis. Bars represent 
the median of three biological replicates. Error bars indicate standard deviation.  
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Figure C5: Max target peak heights show variability across biological. The graph 
above is the first derivative of the melt curve for three replicates of Gal4-EED/luc 
HEK293 cells treated with Cas9-sg32 and ssDNA template. Significant variability 
within the same treatment type was common among each treatment, making it 
difficult to identify small shifts in sequence length from editing. This prohibited 
effective cross-treatment comparisons. We hypothesize that these differences are 
due to the low general efficiency of HDR as compared to NHEJ, a competing 
pathway, which is simultaneously inducing indels and thus changes to the melt 
curve.  
 
 
 
 
 
 
 
 
 
  167 
 
 
Figure C6: Diverse melting temperatures of differently edited sequences in a single 
sample creates challenges for cross-treatment comparison. The graph above is the 
first derivative of the melt curve for three distinct treatments of Gal4-EED/luc 
HEK293 cells with Cas9-sg32 and ssDNA template. While all three are different 
treatments, their maximum target peak height is nearly identical, most likely due to 
the variety of edited sequence types within each sample. Given the difficulty of peak 
height interpretation, we abandoned this method for cell sorting and Synthego ICE 
for the detection of Cas9-induced indels from NHEJ as opposed to HDR, which has a 
notoriously low efficiency.  
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